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BOOK 1: INTRACELLULAR MECHANISM OF WNT/β-CATENIN SIGNAL 
TRANSDUCTION 
 
 
 
CHAPTER 1: INTRODUCTION TO CELL SIGNALING 
 
 
 
Introduction 
 
 The Wnt/β-catenin signaling pathway is highly conserved throughout metazoan 
and is required for the coordination of diverse developmental programs, stem cell 
maintenance, cell growth and cell proliferation.  Multiple disease states have been 
attributed to the misregulation of Wnt/β-catenin signaling; most notably colorectal cancer 
in which upwards of 80% of tumors contain a mutation that renders the pathway 
constitutively active.  Normally, the pathway is activated when the Wnt ligand binds to 
the Frizzled and low-density lipoprotein receptor related protein 6  (LRP6) receptors 
resulting in inhibition of phosphorylation and degradation of the co-transcriptional 
activator β-catenin.  Elevated levels of β-catenin translocate to the nucleus and activate 
target gene expression.  Within Chapter 2 and 3, I describe our findings on the 
coordination and regulation of the early intracellular signaling events that result in β-
catenin stabilization.  Chapter 1 provides a framework for the following Chapters 
including an introduction to cellular signaling, G protein signaling, and Wnt/β-catenin 
signaling. 
 
How a cell communicates 
 Cells are remarkable communicators. Communication is the means by which cells 
understand their environment, maintain relationships with their surroundings, and in turn 
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provide cues to other cells and tissues. Just as humans have created a multitude of 
methods of communication, cells too have evolved intricate means of communicating.  It 
is by these intricate means of communication that a single fertilized cell develops into an 
embryo with specific tissues. Specialized tissue develops further into organ systems, and 
these organ systems maintain homeostasis. On the simplest level, cells communicate by 
creating a signal that is sent to another cell.  After recognition of the signal, the cell 
processes the signal and a response is produced.  The mechanism by which a cell 
recognizes, processes, and responds to a signal is termed signal transduction.   
 Signal transduction governs and coordinates developmental processes in all 
metazoans.  We understand this in great part from the work of Hans Spemann in the early 
1900’s.  At this time, the events that transpired during embryonic development eluded 
many.  To this end, in his Nobel Lecture in 1935, Hans Spemann stated  
“How does that harmonious interlocking of separate processes come about which makes 
up the complete process of development? Do they go on side by side independently of 
each other (by "self-differentiation", Roux), but from the very beginning so in 
equilibrium that they form the highly complicated end product of the complete organism, 
or is their influence on each other one of mutual stimulation, advancement or limitation?” 
 
Hans Spemann, along with Hilde Mangold, observed that transplantation of the dorsal lip 
of the blastopore from an amphibian embryo entering gastrulation onto the opposite side 
of another embryo resulted in formation of two body axes in the graphed embryo.  One of 
the two axes was formed from the endogenous dorsal lip of the embryo while the other 
was formed from the grafted dorsal lip tissue.  Tissue that would normally have formed 
the ventral side of the animal, instead, developed into a complete dorsal axis when the 
dorsal lip was graphed on it.  The dorsal lip was then coined the organizer since it was 
able to redirect the fate of the tissue on which it was grafted (Spemann and Mangold, 
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2001).	  	  This landmark discovery provided crucial evidence that cells signal to one another 
to induce changes and coordinate developmental processes.  For this work Spemann was 
awarded the Nobel Prize in Medicine or Physiology in 1935.   
 To date 18 signaling pathways have been identified.  In general, all signaling 
pathways utilize a similar mechanism to transduce a signal.  A ligand is released into the 
extracellular environment and bound by a cell surface receptor.  This receptor-ligand 
interaction results in receptor activation and subsequent transduction of the signal into the 
cell.  Intracellular signal transduction is accomplished by second messengers, or cellular 
switches, that pass the signal from one messenger to another until the final message is 
received resulting in a physiological response such as movement, transcriptional 
activation, cell death, etc.    
 Of the 18 signaling pathways identified, 5 pathways have been attributed to 
coordinating the events of metazoan development (Gerhart, 1999).  While the conserved 
core processes (including mitosis, histone/DNA chromatin complexes, membrane 
dynamics, etc) of simple eukaryotes were established at least 2 billion years ago, the 
coordination of mutli-cellularity that has evolved since that time. Much of this 
coordination is due to the evolution of signaling pathways that allow cell-cell 
communication, which was not required for the survival of the simple single-celled 
eukaryote. The evolution of body plan is attributed to the Cambrain period (543-505) in 
which all existing members of each phyla were present.  It has been observed that species 
from diverse phyla, such as flatworms and mice, are composed to the same tissue types 
during development, although the organization of these tissues differs.  Essentially 5 
	   4 
signaling pathways (including the Wnt/β-catenin signaling pathway), which are also 
conserved through these diverse phyla, regulate this organization (Gerhart, 1999).  
 To a certain extent, it is unfortunate that mechanisms of signal transduction are 
coined pathways.  A pathway suggests that there is only one direct way by which a signal 
can be sent from a source to produce a directed outcome of a cell.  It also suggests that 
each pathway functions independently of the others.  However, evidence suggests that 
crosstalk exists between pathways, such that activation of a receptor of one pathway can 
affect the outcome of another signaling pathway. Additionally, second messengers of one 
signaling mechanism can be used to transduce the signal of another signaling system. 
Mechanisms of signal transduction may exist more as a signaling network than a 
signaling pathway (van Amerongen and Nusse, 2009). 
 
Historical Perspective: G protein Signaling 
 The first glimpse of a mechanism for cell signaling came in 1957 with the 
discovery of cyclic AMP (cAMP) and adenylyl cyclase (AC) by Rall and Sutherland. For 
this work Sutherland was awarded a Nobel Prize in Medicine or Physiology in 1971 
(Berthet et al., 1957a) (Sutherland and Rall, 1958).  They had observed that the kinase 
that phosphorylates glycogen could be activated by challenge with the hormones 
epinephrine and glucagon (Robinson and Sutherland, 1971) as well as treatment with 
fluoride.  This same response was identified in canine liver homogenates (Berthet et al., 
1957b), which produced a heat soluble factor produced by the enzyme adenylyl cyclase 
(AC) that was later crystallized and identified as cAMP (Berthet et al., 1957a; Sutherland 
and Rall, 1958). At this time, it was thought that the receptor, which received the 
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hormone signal, also produced AC activity.  Evidence from biochemical and genetic 
studies later indicated that the receptor and AC were two individual proteins.  These 
studies utilized a murine lymphoma cell line sensitive to high levels of cAMP.  After 
selection of a population of cells that were resistant to the high cAMP levels, cells were 
identified to have wild type ligand binding capabilities but no AC activity (Insel et al., 
1976).   In addition, turkey erythrocytes lacking AC activity while containing functional 
receptors were fused with erythroleukemic cells containing a functional AC that lack 
functional receptors.  The resulting fused cells were able to respond to the agonist and 
produce cAMP, indicating that the activities of the receptor and AC are independent 
entities (Orly and Schramm, 1976).  
In addition to the receptor (β-adrenergic receptor) and enzyme (AC), evidence 
suggested that a third member of this pathway was involved in the hormone stimulation 
of cAMP production.  Glucagon (the receptor’s ligand) and fluoride stimulation of cAMP 
production was not competitive, and addition of fluoride could not stimulate cAMP 
production beyond glucagon.  This suggested that fluoride acted on a different site than 
glucagon (Birnbaumer, 1991).  Also, hormonal stimulation of AC was dependent on the 
presence of GTP, GDP, or GMP-PCP, and each was equally effective at stimulating AC 
activity (Rodbell et al., 1971). In the absence of a hormone, Gpp(NH)p, a non-
hydrolyzable analog of GTP, was found to maximally stimulate AC activity.  This 
indicated that AC system involved a GTPase, which was active in the presence of GTP.   
 Cassel and Selinger demonstrated that GTP was hydrolyzed in turkey erthrocyte 
membranes in the presence of catecholamines, and that this activity was dependent on 
magnesium and blocked by addition of an antagonist (Cassel and Selinger, 1976).  They 
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proposed a model whereby AC is bound by GDP in its basal state and activation of AC 
results in replacement of GTP for GDP.  Challenge with hormones resulted in hydrolysis 
of the bound GTP to GDP by AC, placing AC back into its basal state (Cassel and 
Selinger, 1976).  At this time, it was also found that cholera toxin activated AC activity 
but inhibited GTPase activity stimulated by catecholamines (Cassel and Selinger, 1977; 
Sharp and Hynie, 1971). 
 Additional genetic and biochemical evidence from other groups challenged the 
Cassel and Selinger model and suggested that another protein could be attributed with the 
guanine nucleotide dependence.  A mutant S49 lymphoma cell line, termed cyc-, was 
identified to be resistant to β-adrenergic receptor agonists, fluoride, Gpp(NH)p, and 
cholera toxin, but not addition of cAMP.  This indicated that AC is functional in these 
mutant cells and is a separate entity from the guanine nucleotide regulated protein 
(Bourne et al., 1975).  It was the work of a number of independent groups that together, 
through the use of alternative methods, identified a protein that is distinct from the 
receptor and AC that comprised the guanine nucleotide dependent signal transduction 
activity. Protein eluded from a GTPγS sepharose resin from lysate treated with fluoride 
and detergent could add guanine nucleotide regulation back to its flow-through (Pfeuffer, 
1977). Also, sucrose density gradient centrifugation revealed a 42kDa protein that co-
migrated with AC activity.  Another group solubilized and combined membranes from 
the cyc- cell line (lacking detectable AC activity while expressing wild type receptors) 
and mouse L cells (containing wild type AC while lacking receptors) and obtained AC 
activity after treatment with agonist, fluoride and guanine nucleotide (Ross and Gilman, 
1977b).  After killing the AC activity in the L cell extract, and addition to the cyc- 
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membranes, they were able to recapitulate guanine nucleotide, fluoride, and hormone-
stimulated activity (Ross and Gilman, 1977a) (Ross et al., 1978).  The culmination of 
these studies provided strong evidence that another player, separate from the receptor and 
AC, served as a transducer between the receptor and AC.  
 Purification of the AC regulator subunit (Gs) was accomplished by analyzing 
GTP and fluoride-stimulated AC activity in the cyc- membranes (Northup et al., 1980; 
Sternweis et al., 1981).  Gs were found to be composed of three polypeptides, later 
named Gα, β, and γ.  It was also determined that while these polypeptides were absent in 
the cyc- membranes, but present in wild type S49 wild type membranes, consistent with 
previous experiments in cyc- membranes (Johnson et al., 1978).  Al Gilman and Martin 
Rodbell were awarded the Nobel Prize in Medicine of Physiology in 1994 for their 
discovery of heterotrimeric G proteins and G protein signaling. 
 
Heterotrimeric G protein Signaling 
 In a simplified model of heterotrimeric G protein signaling, a ligand binds to a G 
protein coupled receptor (GPCR) resulting in a conformational change such that the 
GPCR Gα protein has decreased affinity for its bound GDP (Figure 1.1).  Because the 
intracellular concentration of GTP is higher than GDP, Gα quickly becomes bound to 
GTP.  The Gα subunit is in an inactivate state when bound to GDP and active when 
bound to GTP.  The activated Gα dissociates from the Gβγ dimer, and each of the 
dissociated subunits can interact with effector proteins.  The length of effector activation 
is dictated by the intrinsic rate of GTP hydrolysis, as well as by Gα’s interactions with 
GTPase Activating Proteins (GAP). Once GTP is hydrolyzed to GDP, the Gα subunit is 
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returns to its inactive state, binds Gβγ, associates with its receptor, and is ready for 
another round of G protein activation. 
 GPCRs represent one of the largest families of proteins in the human genome.  
The distinguishing feature of this family of proteins is the presence of seven α-helical 
transmembrane domains. 27% of all Food and Drug Administration (FDA)-approved 
drugs target this protein family (Williams and Hill, 2009), indicating that GPCRs are of 
interest to the pharmaceutical industry.  Although present in lower eukaryotes (i.e. yeast 
and slime molds), GPCRs evolved 530 million years ago along with the appearance of 
multicellular organisms (Brown, 2007).  The International Union of Pharmacology 
Committee on Receptor Nomenclature and Drug Classification has classified human 
GPCRs in 4 main categories based on sequence comparison; Class one is typified by 
rhodopsin, Class two is typified by the secretin receptor, Class three is typified by the 
glutamate receptor, and Class four is typified by the frizzled and smoothened receptors 
(Foord et al., 2005).  Together, there are approximately 360 known functional GPCRs in 
the human genome. 
Although originally identified to regulate cAMP levels, heterotrimeric G proteins 
have been found to mediate a number of signal transduction pathways.  Currently there 
are 16 genes for Gα subunits in mammals (Table 1.1).  Based on sequence similarity, Gα 
subunits have been separated into four families; Gs, Gi, Gq, and G12.  The types of 
proteins that Gα subunits interact with and activate, or effecter proteins, are as diverse as 
enzymes and ion channels (Table 1.1) (Cabrera-Vera et al., 2003).  Also, the rate of 
nucleotide exchange (the amount of time it takes for a Gα subunit to release GDP and 
bind GTP), which is the rate-limiting step in G protein activation, varies greatly between 
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Figure 1.1 Cycle of heterotrimeric G protein activation.  Starting in the top left hand 
corner, in the resting state, of off state, the heterotrimer is in association with a GPCR at 
the plasma membrane and the Gα subunit is bound to GDP.  Ligand binding to the G 
protein coupled receptor (GPCR) results in a conformational change such that the GPCR 
induces its associated Gα protein to exchange its bound GDP for GTP rending the Gα 
subunit active. The activated Gα dissociates from the Gβγ dimer and each of the 
dissociated subunits can interact with effector proteins.  The length of this dissociation is 
dictated by the intrinsic rate of GTP hydrolysis as well as the by Gα’s interactions with 
GTPase Activating Proteins (GAPs). Once GTP is hydrolyzed to GDP, the Gα subunit is 
placed back into its inactive state, binds Gβγ, and associates with its receptor ready for 
another round of G protein activation. 
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Table 1.1 Gα  families and effectors 
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individual Gα subunits. For example, the dissociation rate of Gαi2 is 0.07 min-1 at 30°C 
while Gαq has an extremely low affinity for GTP in the absence of an activated receptor 
(Hepler et al., 1993; Linder et al., 1990). 
Originally thought to function as a regulator of Gα protein activity, Gβγ subunits 
are also a diverse class of proteins that can interact with and activate numerous effectors 
(Table 1.2).  Five Gβ units and twelve Gγ subunits have been identified in both human 
and mouse genomes. Gβ and γ are always found in complex, however the variability in 
the composition of this dimer has not been correlated to signaling potential, except for 
Gβ1γ1 which has only been shown to associate with Gαt in the visual system (Smrcka, 
2008).  Similar to Gα, Gβγ interacts with and activates a number of proteins, including 
dynamin, ion channels, and phosphoinositide 3 kinase γ (Smrcka, 2008).   
 Both Gα and βγ are post-translationally modified with lipid modifications 
promoting their membrane association. All Gα subunits (except Gαt) are palmitolyated 
and Gi family are also myristoylated.  Gγ subunits are isoprenylated, and this 
isoprenylation is required for Gβγ membrane localization.  These lipid modifications are 
not only required for proper localization of Gα and Gβγ, but also for their interaction 
with effectors and receptors (Taussig et al., 1993; Yasuda et al., 1996; Cabrera-Vera et 
al., 2003) . 
Crystal structures of inactive (GDP-bound) and active (GTP-bound) Gα, Gβγ, and 
the heterotrimeric Gαβγ have provided invaluable insight into the mechanism of 
heterotrimeric G protein activation (Coleman et al., 1994; Lambright et al., 1994; 
Lambright et al., 1996; Noel et al., 1993; Sondek et al., 1994; Wall et al., 1995).  These  
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Table 1.2 Gβγ  effector proteins 
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structures reveal that Gα contains a GTPase domain and a helical domain.  It is the 
helical domain that is the most divergent between Gα subunit families indicating that this 
region determines its effector and receptor interactions.  Three flexible regions within 
Gα, as well as regions in the N and C terminal regions of Gα, appear to be responsible 
for the conformation change in Gα after receptor activation. In addition, this 
conformational change allows for nucleotide exchange (Marin et al., 2001).  Gβγ 
interacts with Gα though a hydrophobic pocket present on Gα.  Gβ is composed of a     
β-propeller with seven WD-40 repeats.  The Gγ subunit tightly interacts with Gβ’s 
coiled-coil domain such that Gβ and γ can only be separated under denaturing conditions 
(Smrcka, 2008).   
 In addition to the GPCR, heterotrimeric G proteins, and the G protein’s effector, 
other players in the G protein signaling pathway further regulate signaling.  One such 
protein is a Regulator of G-protein Signaling (RGS) domain containing protein.  The 
RGS domain is a conserved 130 amino acid sequence that was identified in different 
genes at the same time by different groups (De Vries et al., 1995; Druey et al., 1996; 
Koelle and Horvitz, 1996).  These RGS domain containing proteins bind Gα-GTP and 
accelerate its intrinsic GTPase activity by stabilizing the transition state for GTP 
hydrolysis.  For this reason, RGS proteins are called GAPs, or GTPase Activating 
Proteins (De Vries et al., 2000).  The GAP activity of RGS proteins provides significant 
means of negatively regulating G proteins signaling (Berman et al., 1996).  RGS proteins 
can also inhibit Gα activity by binding and physically preventing Gα interaction with 
effectors (Hepler et al., 1997), as well as diminish Gβγ signaling by accelerating 
heterotrimer reformation (De Vries et al., 2000).  A RGS domain is typically composed 
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of 9-α helices (Tesmer et al., 1997).  Within the human genome, there are 37 genes 
containing at least one RGS domain.  These genes are further classified into 8 subfamilies 
(Soundararajan et al., 2008).   Some RGS proteins often contain other structural protein 
domains, such as PDZ (PSD95/DlGα/zo-1) and DEP domains (Dishevelled/EGL-
10/Pleckstrin), which have been shown to be important for regulating G protein signaling 
(Ballon et al., 2006; Tsunoda et al., 1997).   
 Arrestins are another class of proteins that regulate heterotrimeric G protein 
signaling.  This class of proteins is classified as adaptor proteins that modulate 
desensitization and trafficking of GPCRs.  Within the arrestin family there are four 
members, only two of which are expressed outside the visual system.  Arrestins function 
either by inhibiting GPCR interaction with G proteins or by inducing clathrin-mediated 
endocytosis of the GPCR. (Buchanan and DuBois, 2006). 
 Targeting heterotrimeric G proteins signaling pathways as avenues for treatment 
of disease and illness has been a lucrative endeavor.  Successful treatments for conditions 
as diverse as high blood pressure and depression have targeted various G protein coupled 
signaling pathways (Donati and Rasenick, 2003; Lindsey et al., 2009).  Because G 
proteins signal to coordinate cell movement, differentiation, and gene expression, G 
protein signaling pathways have been proposed to be promising targets for novel 
chemotherapies and cancer treatments.  
 
Historical Perspective: Wnt/β-catenin signaling 
The history of Wnt signaling is a beautiful culmination of discoveries from many 
disciplines of biological investigation that spans over 30 years.  The history of Wnt/       
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β-catenin signaling highlights this signaling pathways role in both development and 
disease. 
In 1975, a Drosophila mutant lacking wings and halteres, named wingless, was 
reported (Sharma and Chopra, 1976).  Based on the mutant phenotype, the wingless locus 
was hypothesized to be involved in development.  This hypothesis was confirmed a few 
years later when Nusslein-Volhard and Wieschaus identified wingless as a segmentation 
coordination gene in a Drosophila mutagenesis screen for genes required for 
segmentation (Nusslein-Volhard and Wieschaus, 1980). For identifying genes required 
for segmentation, including wingless, Nusslein-Volhard and Wieschaus were awarded the 
Nobel Prize in Physiology or Medicine in 1995.   
Two years later, Nusse and Varmus identified the mammalian homolog of 
wingless while investigating for novel oncogenes by analyzing mouse mammary tumor 
virus (MMTV) insertion sites that resulted in tumorigenesis (Nusse and Varmus, 1982; 
Rijsewijk et al., 1982). Injection of mouse int-1 RNA into Xenopus leavis embryos 
resulted in dual axis formation, indicating that much like Drosophila int-1, or wg, mouse 
int-1 was not only an oncogene, but also involved in patterning vertebrates (McMahon 
and Moon, 1989).  This further substantiated current thought that cellular oncogenes 
function normally to coordinate development in metazoan organisms (Bishop, 1983).  To 
provide clarity to this new field of study, a mnemonic for wingless and Int-1 gave birth to 
the term Wnt (Nusse et al., 1991). 
 Mutagenesis screens for genes that regulate patterning in the Drosophila embryo 
identified multiple genes that were later found to be part of a Wnt signaling pathway.  
These genes, named after the phenotype shown in their segmentation or polarity defect, 
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include armadillo (the Drosophila ortholog of β-catenin) (Wieschaus and Riggleman, 
1987), dishevelled (Dsh) (Perrimon and Mahowald, 1987), shaggy (the Drosophila 
ortholog of glycogen synthase kinase 3, GSK3)(Ripoll et al., 1988), and frizzled (Fz) 
(Schubiger and Palka, 1986).  Further genetic analysis placed these genes in the Wnt 
pathway in the following order; wg signals through fz to inhibit shaggy, and dishevelled 
and armadillo are downstream of wg (Bhanot et al., 1996; Noordermeer et al., 1994; 
Siegfried et al., 1992).  Further genetic and biochemical analysis provided additional 
insight into the mechanism of signaling. 
 Negative regulators of the pathway were identified first by their effect in 
vertebrates. In 1949, the Fused mutant mouse was identified and described by axis 
duplication in embryos.  Injection of RNAs for this gene in Xenopus embryos resulted in 
a loss of body axis indicating that this gene was a negative regulator of Wnt signaling 
(Zeng et al., 1997).  To avoid confusion with the unrelated Drosophila gene fused, this 
gene was named Axin, for axis inhibition.  Another negative regulator of the pathway, 
Adenomatous Polyposis Coli (APC), gained attention early due to its linkage to colon 
cancer (i.e. familial adenomatous polyposis). β-catenin was identified in APC 
immunoprecipitates (Rubinfeld et al., 1993), and APC was found to regulate the stability 
of β-catenin such that expression of APC results in reduced β-catenin levels in SW480 
cell line, known to have high levels of β-catenin and a mutant APC (Munemitsu et al., 
1995). 
 Additional Wnt signaling components were identified in the 1990’s and early 
2000’s by a combination of methods.  One example of this is the LRP5/6, low density 
lipoprotein related receptor 5/6.  LRP6 was identified by Drosophila genetics (Wehrli et 
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al., 2000), mouse genetics (Pinson et al., 2000), and Xenopus injection studies (Tamai et 
al., 2000).   
 The Wnt ligand can signal independently of β-catenin to activate two addition 
pathways; the Planar Cell Polarity (PCP) pathway that signals through small GTPases 
including Rac and Rho, and the Wnt/Ca2+ pathway which signals through Jun kinase 
(JNK). These pathways utilize a number of proteins that function in the Wnt/β-catenin 
pathway, however, it is not understood the extent of cross talk within the Wnt signaling 
pathways.  These “noncanonical” Wnt pathways will not be discussed at this time.  
 
Current Models of Wnt/β-catenin Signaling 
 The key to canonical Wnt signaling is regulating cytosolic and nuclear levels of 
the cotranscriptional activator β-catenin.  When the Wnt pathway is off or inactive, 
cytosolic β-catenin is maintained at a low level by the action of the β-catenin destruction 
complex.  When the pathway is “on”, the destruction complex is inhibited, the cytosolic 
level of β-catenin increase, and β-catenin can enter the nucleus to activate a Wnt 
transcriptional program (Figure 1.2). 
 The β-catenin destruction complex is responsible for maintaining low levels of 
cytosolic β-catenin in the cell.  The destruction complex includes the scaffold proteins 
Axin and APC, and the kinases GSK3 and Casein Kinase I α (CK1α). Through specific 
binding domains, Axin interacts with GSK3, CK1α, and β-catenin to coordinate the 
series of phosphorylation events required to mark β-catenin for degradation.  CK1α 
phosphorylates β-catenin at serine 45 to prime β-catenin for phosphorylation at serines 33 
and 37, and threonine 41 by GSK3 (Amit et al., 2002; Liu et al., 2002).  These sites of 
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phosphorylation provide a recognition site for its E3 ubiquitin (Ub) ligase (β-TRCP), 
resulting in its subsequent ubiquitination and degradation by the proteasome (Hart et al., 
1999; Latres et al., 1999).  Additionally, GSK3 and CK1α phosphorylate APC and Axin, 
resulting in their increased association with β-catenin (Jho et al., 1999; Rubinfeld et al., 
2001; Xing et al., 2004), further enhancing β-catenin degradation (Lee et al., 2003). 
Consistent with their roles within the destruction complex, both Axin and APC are tumor 
suppressors. 
 The relationship between APC and Axin is somewhat paradoxical.  Axin levels 
have been calculated to be exceedingly lower then other Wnt pathway components in 
Xenopus oocytes, suggesting that modulation of Axin stability could be a point of 
pathway regulation (Lee et al., 2003).  In Drosophila, APC plays a positive role in 
Wingless signaling by promoting degradation of Axin.  Additionally, the domain of APC 
that is required for APC-mediated Axin degradation is not the same domain that interacts 
with β-catenin (Takacs et al., 2008).  Conversely, Axin over-expression can facilitate 
ubiquitin-mediated degradation of APC (Choi et al., 2004).   
Wnt ligands, for which the pathway was named, activate the Wnt signaling 
pathway.  This is a conserved family of 19 ligands present in all metazoans.  They are 
cysteine rich proteins that are ~350-400 amino acids in size. Wnt ligands are  
glycosylated, (which is required for secretion) and lipidated, contributing to the 
hydrophobicity and poor solubility of the Wnt ligand (Komekado et al., 2007).    
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Figure 1.2:  Schematic of Canonical Wnt Signaling.  In the absence of a Wnt ligand 
(left side of figure), β-catenin concentrations are kept low in the cytoplasm through the 
action of the destruction complex, which consists of two scaffold proteins, Axin and the 
adenomatous polyposis coli (APC) protein, as well as a kinase, glycogen synthase kinase 
3 (GSK3).  The GSK3 in destruction complex phosphorylates β-catenin resulting in its 
recognition by an E3 ubiquitin ligase and its subsequent polyubiquitination and 
proteasome-mediated degradation.  In the presence of a Wnt ligand (right side of figure), 
the ligand binds co-receptors Fz and LRP5/6, resulting in inhibition of destruction 
complex.  Since the destruction complex is inhibited, β-catenin is not degraded and it 
accumulates in the cytoplasm.  β-catenin can then translocate to the nucleus and interact 
with transcription factors of the T cell factor/lymphoid enhancer factor (TCF/LEF) family 
that activates a transcriptional program.  Figure adapted from (Tolwinski and Wieschaus, 
2004).    
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  To activate the Wnt pathway, the Wnt ligand binds to the Frizzled and LRP5/6 
co-receptors.  The Frizzled receptor contains seven α-helical transmembrane domains 
and LRP5/6 contains a single transmembrane domain. Both of these receptors are 
required to transduce a Wnt signal intracellularly.  In mammals, there are 10 Frizzled 
genes, and only one LRP5 and one LRP6.  When comparing LRP5 and 6, LRP6 is 
required for embryogenesis (Pinson et al., 2000) while LRP5 is required for bone 
homeostasis (Kato et al., 2002).  However, both genes must have some redundant roles in 
development since mice homozygous null for LRP5 and 6 die during gastrulation, earlier 
than homozygous LRP6 mutant alone. LRP6 also exhibits stronger signaling activity in 
both Xenopus (Tamai et al., 2000) and mammalian cells (Holmen et al., 2002). Based on 
this difference in activity, I will only refer to LRP6.  
A key event in Wnt signaling is activation by phosphorylation of the intracellular 
domain of LRP6.  The intracellular domain of LRP6 (as well as LRP5 and the Drosophila 
ortholog arrow) contains 5 repeated PPPSPxS motifs (P, proline; S, serine or threonine; 
x, variable residue).  This intracellular domain alone is able to activate Wnt signaling 
(Mao et al., 2001a; Mao et al., 2001b) and a mutant lacking this domain is unable to 
transduce a Wnt signal and acts in a dominant negative fashion to inhibit Wnt and Fz 
signaling (Tamai et al., 2000).  These PPPSPxS motifs in the intracellular domain of 
LRP6 are thought to be dually phosphorylated by the same kinases that phosphorylate β-
catenin; GSK3 and CK1 (Davidson et al., 2005; Zeng et al., 2005).  In contract to the β-
catenin, GSK3 is the priming kinase for CK1 and it appears that the GSK3 
phosphorylation of LRP6 is Wnt induced (Pan et al., 2008).  In support of this, the 
GSK3α/β null ES cells lack most, if not all, Wnt induced LRP6 phosphorylation (Zeng et 
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al., 2008). The phosphorylated PPPSPxS motifs provide a binding domain for Axin such 
that Axin is recruited to the membrane after Wnt stimulation (Davidson et al., 2005; 
Tamai et al., 2004; Zeng et al., 2005).  Additionally, GSK3 bound to Axin mediates 
further LRP6 phosphorylation (Zeng et al., 2008).   
Frizzled function is required for LRP6 phosphorylation and activation (Zeng et 
al., 2008). Frizzled signaling has been linked to Dishevelled (Dsh).  Frizzled and 
Dishevelled were identified to interact through the PDZ domain of Dsh and the c-
terminal domain of Fz (Wong et al., 2003). Dsh has been shown to be recruited to the 
membrane after Wnt stimulation (Umbhauer et al., 2000).   
Dishevelled is a 500-600 amino acid scaffold protein composed of DIX, PDZ, and 
DEP domains as well as a SH3 protein-binding motif (Wallingford and Habas, 2005). 
Mammals have three Dishevelled genes; (Dvl1, Dvl2, Dvl3) while model organisms, 
such as Drosophila and Xenopus, only have one Dishevelled gene (Dsh).  For the sake of 
simplicity, I will refer to Dishevelled as Dsh, unless a study sited a specific mammalian 
Dishevelled, or Dvl.   
Fz-Dsh interaction and Dsh function are required for LRP6 activation and 
phosphorylation (Bilic et al., 2007; Zeng et al., 2008). Dsh and Axin have been shown to 
interact (Itoh et al., 2000; Kishida et al., 1999).  One model for LRP6 activation proposes 
that Fz-Dsh interaction recruits Axin-GSK3 to the membrane, and that GSK3 on Axin 
phosphorylates and activates LRP6 (Zeng et al., 2008).  One weakness in this model is 
that the intracellular domain of LRP6 must be phosphorylated by GSK3 for Axin to bind. 
Axin, however, is recruited to the membrane after LRP6 phosphorylation.  One source of 
GSK3 is Axin bound GSK3.  This model suggests a feed-forward loop that amplifies the 
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GSK3 phosphorylation on LRP6.  In support of this model, loss of one PPPSPxS domain 
results in loss of LRP6 signal and loss of two or more PPPSPxS domain results in a 
substantial loss of signaling capacity.  This indicates that there is a requirement for full 
phosphorylation in order to transmit a signal through the activated LRP6 receptor 
(MacDonald et al., 2008; Wolf et al., 2008). A model that supports this stepwise 
activation of LRP6 by phosphorylation is an “initiation and amplification” model.  The 
“initiation” step requires both Frizzled and Arrow (Drosophila LRP5/6 ortholog).  In 
support of this model, a Frizzled-Arrow fusion is unable to fully rescue an arrow- mutant, 
indicating that Arrow/LRP6 serves a second downstream function to amplify signaling 
(Baig-Lewis et al., 2007). In addition, a chimeric Arrow protein containing the Torso 
dimerization domain potentiated Wingless (Wg) signaling, but is unable to initiate a Wg 
signal on its own.  This suggests that Arrow dimerization, which is believed to take place 
after signal initiation, is not enough to initiate signaling. However, coexpression of the 
Fz/Arr chimera and the chimeric Arr resulted in a synergistic activation of signaling to 
the level of Wg expression itself.  This implies that both initiation and amplification are 
required for robust Wg signaling (Baig-Lewis et al., 2007). Another model for LRP6 
activation requires Fz-LRP6 clustering driven by Dvl, Axin, and GSK3 to form a 
“signalosome” (Bilic et al., 2007). In this model, Wnt stimulates Dvl mediated 
coaggregation of LRP6 with other Wnt signaling components (including Fz8, Axin, and 
GSK3) forming a “signalosome” which triggers CK1γ phosphorylation of LRP6.  It has 
been proposed that Dvl (the mammalian ortholog of Xenopus Dsh) and Axin form large 
complexes with additional Wnt components that allow for weak yet dynamic interaction 
(Schwarz-Romond et al., 2007).  In support of this theory, the DIX domain of Dvl is 
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required for Wnt induced receptor-complex formation (Bilic et al., 2007; Schwarz-
Romond et al., 2007). Taken together, Wnt signaling stimulates dynamic protein 
interactions that culminate on LRP6 activation. 
There are two schools of thought surrounding Wnt mediated inhibition of            
β-catenin phosphorylation; one is LRP6 dependent, while the other is LRP6 independent.   
Constitutively active LRP6 can inhibit β-catenin degradation, assumably independent of 
Fz and Dsh (He et al., 2004).  Recent evidence suggests that phosphorylated LRP6 can 
directly inhibit β-catenin phosphorylation, resulting in β-catenin stabilization (Cselenyi et 
al., 2008; Piao et al., 2008; Wu et al., 2009).  It has also been reported that β-catenin at 
the membrane is dephosphorylated in response to Wnt (Hendriksen et al., 2008).  In 
support of a LRP6 independent β-catenin phosphorylation mechanism, over-expression 
of Dsh in Drosophila or addition of recombinant Dsh into Xenopus egg extract results in 
β-catenin stabilization in the assumed absence of LRP6 (Salic et al., 2000; Wehrli et al., 
2000).  Another mechanism for inhibition of β-catenin degradation involves dissociation 
of destruction complex or stimulation of Axin degradation by recruiting Axin away from 
the destruction complex to LRP6 or to Fz-Dsh at the membrane (Cliffe et al., 2003; 
Tamai et al., 2004).  Also, Gαo signaling through Fz, as well as Protein Phosphatase 2 
(PP2) dephosphorylation, has been proposed to lead to the dissociation of GSK3-Axin 
and disruption of the destruction complex (Liu et al., 2005; Luo et al., 2007).  It has also 
been reported that Axin is degraded in response to signaling in Xenopus egg extract and 
Drosophila (Lee et al., 2003; Mao et al., 2001b; Tolwinski et al., 2003), although LRP6 
can still inhibit β-catenin independent of Axin degradation (Cselenyi et al., 2008).  
However, the timing of Axin degradation lags behind β-catenin stabilization, suggesting 
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that destabilization of Axin is not a primary means of stabilizing β-catenin, but instead 
may serve to augment the length of time that the pathway is activated (Liu et al., 2005; 
Willert et al., 1999; Yamamoto et al., 1999).   
In addition to signaling through the Frizzled and LRP6 receptors, studies in 
Drosophila, C. elegans and mice have identified atypical receptor tyrosine kinases (RTK) 
of the Ryk or Ror families function as Wnt receptors as well (Forrester et al., 2004; Green 
et al., 2007; Lu et al., 2004). In Wnt/β-catenin signaling, Ryk binds Wnt-3a and Fz to 
form a tertiary complex.  The intracellular domain of Ryk interacts with Dsh, which is 
required for TCF activation in response to Wnt.  Signaling through Ryk is vital for Wnt3a 
induction of neurite outgrowth of basal root ganglia (Lu et al., 2004).  Roles for RTK and 
Ror have also been implicated in Wnt/JNK signaling (Minami et al., 2009; Oishi et al., 
2003). 
 
Heterotrimeric G proteins in Wnt/β-catenin Signaling 
 Ever since the Frizzled receptor was cloned and identified to contain seven α-
helical transmembrane domains (Vinson et al., 1989), it has been thought that Fz may 
signal through heterotrimeric G proteins.  A number of heterotrimeric G protein subunits 
as well as classic G protein signaling cascade members have been implicated in Wnt 
signaling. 
Pertussis Toxin (PTX), an exotoxin produced by Bordetella pertussis, inhibits Gi 
family G proteins by ADP-Ribosylating the Gβ subunit thereby inhibiting its interaction 
with effectors and GPCRs.  Wnt8 treatment of mouse F9 teratocarcinoma cells 
expressing Rat Fz-1 results in primitive endoderm (PE) formation. (Liu et al., 1999).  
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PTX treatment of F9 cells inhibits Wnt8 stimulated primitive endoderm formation 
suggesting that Wnt8 signals through Gi family of Gα subunits.  Additionally, PTX 
treatment inhibited signaling through a β2-AR/Fz1 chimeric receptor (containing the 
extracellular and transmembrane domains of the β2-adrenergic receptor fused with the 
intracellular domains of the Frizzled receptor) (Gao and Wang, 2007; Malbon et al., 
2001) inhibited Wnt3a stimulated β-catenin stabilization (Liu et al., 2005).  PTX also 
suppressed effects of Fz over-expression in Drosophila ommatidia (Katanaev et al., 
2005).  Depletion by RNAi of Gαo from F9 cells also inhibited Wnt8 stimulated 
primitive endoderm formation (a read-out of Wnt/β-catenin pathway activation).  
Depletion of Gαq has the same effect as depletion of Gαo (Liu et al., 1999).  Also, 
stimulation of a β2-AR/Fz1 chimeric receptor with β2-AR agonists requires Gαo (Liu et 
al., 2001), Gαo mediates Fz signaling in Drosophila (Katanaev et al., 2005), Gαo 
disrupts the GSK3-Axin2 interaction thereby stabilizing β-catenin (Liu et al., 2005), and 
Gαo binds and recruits Axin to the plasma membrane (Egger-Adam and Katanaev, 
2009).  Gαq is also required for signaling through β2-AR/Fz1 chimeric receptor, and is 
thought to inhibit the destruction complex (Liu et al., 2001; Liu et al., 2005), possibly 
through direct inhibition of GSK3 (Najafi, 2009).  Knockdown of Gαq also abolishes 
Wnt3a stimulated inositol pentaphosphate (IP5) production, whereas overexpression of a 
constitutively active Gαq stimulates IP5 production (Gao and Wang, 2007).  In addition 
to Gαo and Gαq, Gαs and Gα12/13 have been implicated in Wnt/β-catenin signaling.  
Signaling downstream of Prostaglandin E2 (PGE2) stimulates Gαs to bind the RGS 
domain of Axin, resulting in the inhibition and dissociation of GSK3 and subsequent β-
catenin stabilization (Castellone et al., 2005).  Binding of Gα12 and Gα13 to E-cadherin 
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cytoplasmic tails results in the release of membrane bound β-catenin and subsequent 
increase in the cytoplasmic concentration of β-catenin (Meigs et al., 2001).  Additionally, 
Gα12 has been shown to interact with the RGS domain of Axin (Stemmle et al., 2006).  
 Positive and negative roles for Gβγ have been recently implicated for signaling in 
the Wnt/β-catenin pathway.  Gβγ was first identified to interact with Dishevelled through 
a TAP-tag screening approach for novel Dishevelled binding partners (Angers et al., 
2006). Gβ2γ2 has been proposed to provide a feedback mechanism by binding Dsh and 
signaling through phospholipase C (PLC) resulting in Dsh degradation through the 
lysosomal pathway (Jung et al., 2009).  In support of this, injection of Gβ2γ2 RNA into 
Xenopus laevis embryo inhibited axis duplication induced by Xwnt8 or Dsh (Jung et al., 
2009).  Using Drosophila genetics, knock down of Gβ13Fγ1 in Drosophila wings discs 
resulted in the loss of expression of short-range Wg target genes and produced a wg 
phenotype (Egger-Adam and Katanaev, 2009).   The association between Dsh and 
Gβ was also confirmed in this study, concluding that Gβγ interacts with and recruits Dsh 
to the plasma membrane.  However, over-expression of Gβ13Fγ1 in Drosophila wing 
discs resulted in down-regulation of Wg signaling, much like the Xenopus laevis injection 
experiments.  This indicates that Gβγ may play both a positive and negative role in the 
pathway; initial recruitment of Dsh to the membrane by Gβγ can serve to activate 
signaling and sustained or persistent membrane localization results in Dsh degradation 
(Egger-Adam and Katanaev, 2009). 
 Axin and other RGS domain containing proteins have been implicated in Wnt 
signaling.  As previously mentioned, Axin has been proposed to interact with Gα12, 
Gαs, and Gαo through its RGS domain (Castellone et al., 2005; Egger-Adam and 
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Katanaev, 2009; Stemmle et al., 2006).   Although both Gα12 and Gαs were shown to 
preferentially interact with Axin in an active state (GTP bound or treated with aluminum 
fluoride), Axin does not enhance the GTPase activity of the Gα subunits. This suggests 
that Axin does not act as a GAP (GTPase Activating Protein), but rather serves as a 
scaffold to bring signaling proteins in close association like the Gα12/13 RGS-domain 
containing RhoGEFS (Castellone et al., 2005; Stemmle et al., 2006; Tanabe et al., 2004).  
Similar to the phenotype observed after injection of a Wnt negative regulator, injection of 
Xenopus embryos with RNA for rat RGS4 (Gi and Gq GAP) and human RGS2 (Gq 
specific GAP) resulted in a ventralized phenotype (Wu et al., 2000).  rRGS4 was also 
able to inhibit Xwnt-8 induction of axis duplication in Xenopus embryos, suggesting that 
RGS proteins modulate signaling through Wnts by attenuating G protein signaling (Wu et 
al., 2000).   RGS19 was identified in a screen for RGS domain containing proteins to 
inhibit β-catenin signaling.  Expression of constitutively active Gαo rescued Wnt/β-
catenin signaling inhibition by RGS19 suggesting that RGS19 regulates Wnt/β-catenin 
signaling by inactivating Gαo (Feigin and Malbon, 2007).   
 Although Frizzled has not been identified as a bona-fide G protein coupled 
receptor, there are multiple lines of evidence that strongly imply that Frizzled signals 
through heterotrimeric G proteins (Malbon, 2004).  (1) Frizzled is heptahelical, 
containing 7 α-helical transmembrane domains like all other G protein coupled receptors 
(Vinson et al., 1989).  (2) Like other GPCRs, the N-terminus of Frizzled is on the 
extracellular side of the cell, while the C-terminal domain faces the intracellular side.  
The N-terminal domain is multiply N-glycosylated, and the C terminal sides (and internal 
loops) contain multiple predicted sites of phosphorylation, like other GPCRs.                 
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(3) Signaling through Frizzled (or the β2-AR/Fz chimera) is PTX sensitive (Gao and 
Wang, 2007; Katanaev et al., 2005; Liu et al., 1999; Liu et al., 2005; Malbon et al., 
2001). (4) Signaling through Frizzled can be induced by GTP analogs. (Liu et al., 2005). 
(5) There is a decrease in Fz signaling when expression of G proteins is knocked down 
(Gao and Wang, 2007; Katanaev et al., 2005; Liu et al., 2001; Liu et al., 1999), and (6) Fz 
signaling is activated when G proteins expression or activity is enhanced (Katanaev et al., 
2005) (Gao and Wang, 2007). (7) There is an increase in Fz affinity for Wnts when the 
concentration of GTP is low (Liu et al., 2001).  Significantly, Wnt stimulated Fz 
signaling has not been shown to increase Gα nucleotide exchange and Frizzled has not 
been shown to have GEF activity. 
 Although it has not been definitely determined that Fz signals through G proteins, 
multiple known GPCRs have been shown to signal to activate β-catenin signaling (Yi et 
al., 2008) (Malbon, 2005).  Prostanoid receptors, EP2 and EP4, are GPCRs that have 
been shown to signal to stabilize β-catenin and activate β-catenin transcriptional 
activation after activation by PGE2 (Castellone et al., 2005; Fujino and Regan, 2001; 
Fujino et al., 2002).  Signaling through PGE2 requires signaling by Gβγ and Gαs.  When 
activated by PGE2, Gβγ signals through Phosphoinositol 3-kinase (PI3K) to Akt, which  
phosphorylates and inhibits GSK3.  At the same time, Gαs signals to release GSK3 from 
Axin resulting in destruction complex destabilization and subsequent β-catenin 
stabilization (Castellone et al., 2005).  Also, PGE2 signals through cAMP/PKA to 
directly regulate β-catenin signaling in hematopoietic stem cells (HSC) and the 
hematopoietic niche during embryogenesis (Goessling et al., 2009). Another GPCR, the 
lipid metabolite lysophosphatidic acid (LPA) receptor, stimulates cell proliferation in 
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colon cancer cells through stabilization of β-catenin.  This mechanism for β-catenin 
stabilization is through Gq signaling to PKC, which phosphorylates and inhibits GSK3, 
resulting in β-catenin stabilization (Yang et al., 2005). Signaling by the platelet-derived 
growth factor (PDGF) through its GPCR activates the p68 RNA helicase to stimulate β-
catenin nuclear translocation. It is believed to do this by blocking GSK3 phosphorylation 
of β-catenin and displacing β-catenin from Axin (Yang et al., 2006; Yang et al., 2007).   
Although it is not known if this signaling is transduced through heterotrimeric G proteins, 
activation of the parathyroid hormone receptor (PTH1R) GPCR by the parathyroid 
hormone (PTH) in osteoblasts requires activation of the Wnt co-receptor, LRP6, through 
phosphorylation by PKA.  PTH mediated β-catenin stabilization and subsequent 
transcriptional activation has been attributed to the stimulation of bone anabolism (Wan 
et al., 2008). Also, treatment of cells with the Gonadotropin-Releasing Hormone (GnRH), 
which signals though a GPCR, inhibits β-catenin degradation through inhibition of GSK3 
in mouse gonadotrope cells (Gardner et al., 2007). Although it is possible that Frizzled 
itself does not signal through heterotrimeric G proteins, other GPCRs activated by their 
ligands are able to utilize the intracellular Wnt/β-catenin signaling components to 
stabilize β-catenin. 
 β-arrestins, adaptor proteins that modulate desensitization and trafficking of 
GPCRs, have also been implicated to play a role in Wnt/β-catenin signaling.  Mouse 
embryonic fibroblasts (MEFs) genetically depleted of β-arrestin 1 and/or 2 are unable to  
responded to Wnt3a activation of β-catenin signaling (Bryja et al., 2007).  Also injection 
of Xenopus laevis with β-arrestin morpholinos blocked axis duplication when injected 
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with Xwnt8, suggesting that β-arrestins are required for Wnt/β-catenin signaling (Bryja et 
al., 2007). 
 Although there is a body of evidence that indicates that Wnt/β-catenin signaling is 
a G protein coupled signaling pathway, it is still not widely accepted that heterotrimeric 
G proteins moderate Wnt signaling. 
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BOOK 1: INTRACELLULAR MECHANISM OF WNT/β-CATENIN SIGNAL 
TRANSDUCTION 
 
 
 
 
CHAPTER 2: Gβγ  PROMOTES LRP6 MEDIATED β-CATENIN/TCF 
SIGNALING BY STIMULATING MEMBRANE ASSOCIATION AND 
ACTIVATION OF GSK3  
 
 
 
 
Introduction 
 Heterotrimeric G proteins, which consist of a Gα subunit and an associated Gβγ 
dimer, mediate a multitude of physiological responses from a host of diverse ligands. 
Activated G protein-coupled receptors (GPCRs) catalyze exchange of GDP for GTP on 
Gα, resulting in subunit dissociation and G protein activation. The signal is terminated 
upon hydrolysis of GTP by Gα the intrinsic GTPase activity of the Gα subunit and its 
reassociation with Gβγ. Both Gα and Gβγ activate many downstream effectors.  
The Wnt/β-catenin pathway is conserved throughout metazoa and required for 
coordination of diverse developmental programs, stem cell maintenance, and cell growth 
and proliferation. In the absence of a Wnt ligand, cytoplasmic β-catenin levels are kept 
low by the destruction complex, which is composed of Adenomatous Polyposis Coli 
(APC), Axin, and Glycogen Synthase Kinase 3 (GSK3). GSK3 phosphorylates β-catenin, 
thereby marking it for ubiquitination and proteasome-mediated degradation. Binding of 
Wnt to Frizzled and Low-Density Lipoprotein Receptor-Related protein 6 (LRP6) co-
receptors results in inhibition of β-catenin destruction and a subsequent rise in 
cytoplasmic β-catenin levels. β-catenin enters the nucleus to initiate a transcriptional 
program with T cell factor/lymphoid enhancer factor (TCF/LEF) family members 
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(MacDonald et al., 2009). The initial discovery that the Wnt receptor, Frizzled, contains 
seven predicted transmembrane domains, a topology characteristic of GPCRs, suggested 
that Frizzled signals through heterotrimeric G proteins (MacDonald et al., 2008). 
Activation of LRP6 is dependent on phosphorylation of conserved motifs within 
its intracellular domain (Davidson et al., 2005) (Zeng et al., 2005). Previous studies have 
suggested that a pool of Axin-bound GSK3 that translocates to the membrane via 
Dishevelled (Dsh) is responsible for initial phosphorylation of LRP6 at the plasma 
membrane (Zeng et al., 2008; Zeng et al., 2005). Phosphorylated LRP6 provides 
additional docking sites for cytoplasmic Axin-GSK3 complexes to promote further 
phosphorylation of LRP6. Binding of this complex to phospho-LRP6 results in inhibition 
of GSK3 with a subsequent decrease in β-catenin phosphorylation (Cselenyi et al., 2008; 
Piao et al., 2008; Wu et al., 2009). The mechanism for initiation of the early 
phosphorylation events of LRP6 is not known. Our evidence suggests that Gβγ recruits 
and activates GSK3 to phosphorylate LRP6, placing Gβγ in a pivotal role in initiation of 
LRP6 activation. 
 
Methods 
 
Constructs and purified proteins 
Human Gβ1 was subcloned into pCS2-HA vector. hGβ1 alanine mutations were 
constructed using QuikChange site mutagenesis kit (Stratagene) following 
manufacturer’s protocol. Sequence encoding amino acids 493-689 of mouse adrenergic 
receptor kinase β1 was subcloned into pCS2 vector. Gγ2CAAX pCS2 was generated by 
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PCR-based site-directed mutagenesis. Oligonucleotide primer sequences are available 
upon request. All other constructs used have been described previously. Gαs and 
myristoylated GαoA, GαoB, Gαi2, and Gαi3 were expressed and purified from bacteria, 
and Gβ1γ2 and Gαq were purified from Sf9 cells as previously described (Hepler et al., 
1994; Kreutz et al., 2006; Lee et al., 1994; Linder et al., 1990; Ueda et al., 1994). 
Heterotrimeric G proteins were purified from porcine brain (Wampler’s Sausage Factory, 
TN) and Gαt from bovine rod outer segments using previously described protocols 
(Sternweis and Robishaw, 1984) (Papermaster and Dreyer, 1974). Gβγ was concentrated 
to 1 mg/mL in 50 mM HEPES pH 8.0, 1 mM EDTA, 1 mM DTT, 10 mM MgSO4, and 
40 mM β-octyl glucoside. GSK3 and CKI proteins were purchased from New England 
Biolabs. 
 
G protein activation 
To activate GαoA, GαoB, Gαi2, Gαi3, and Gαs, proteins were diluted 1:20 (v/v) with 
50mM HEPES pH 8, 1mM EDTA, 1mM DTT, 10mM MgSO4, and 10µM GTPγS and 
incubated at 30˚C for 30 min. Proteins were concentrated to their original volumes using 
Centricon-10 (Millipore). To activate Gα12, protein was diluted 1:1 (v/v) with 80mM 
HEPES pH 8, 1mM EDTA, 1mM DTT, 22mM MgSO4, 0.05% Lubrol, and 20µM GTPγS 
and incubated at 30˚C for 90mins. Gα13 was activated by diluting 1:1 (v/v) with 80mM 
HEPES pH 8, 1mM EDTA, 1 mM DTT, 3mM MgSO4, 0.05% Lubrol, and 20µM GTPγS 
and incubated at 30˚C for 90mins. Excess GTPγS was removed using Zeba Desalt Spin 
Column (Pierce). To activate purified brain heterotrimer, Gαt, and Gαq, proteins were 
incubated with 10mM NaF, 30µM AlCl3, and 10mM MgCl2 for 45mins on ice. 
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[35S]β-Catenin degradation and phospho-β-catenin assays 
Xenopus egg extract preparation and [35S]β-catenin degradation assays were performed as 
previously described (Salic et al., 2000).  Samples were removed at 0 and 3hr for SDS-
PAGE and autoradiography. To detect β-catenin that has been phosphorylated by GSK3 
in extract, anti-β-catenin-phospho-Ser33/Ser37/Thre41 antibody (Cell Signaling) was 
used for immunoblotting. Anti-α-tubulin (DM1α, Sigma) was control.  
 
TOPflash assay 
HEK-293 STF cells were cultured in DMEM media supplemented with 100units/mL 
penicillin, 100unit/mL streptomycin, 10% FBS. Lipofectamine 2000 transfection reagent 
(Invitrogen) was used for all transfections. Cells were lysed 48hrs post-transfection with 
1X Passive Lysis Buffer (Promega) and luciferase activity measured with Steady Glo 
(Promega). Luciferase activities were normalized to cell number using Cell Titre Glo 
(Promega). 
 
Co-immunoprecipitation studies 
For co-immunoprecipitation from cells, cells were washed with cold PBS and then lysed 
on ice for 30min using non-denaturing lysis buffer (NDLB): 50mM Tris pH 7.4, 300mM 
NaCl, 5 mM EDTA, 1% (w/v) Triton X-100, and protease inhibitors (1mg/ml leupeptin, 
pepstatin, and chymostatin). Lysates were diluted to 1mg/ml with NDLB and incubated 
with antibody beads for 3hrs with rotation at 4˚C. Beads were then washed 3X with 
NDLB and 1X with PBS. Proteins were eluted from beads with sample buffer and 
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processed for SDS-PAGE followed by immunoblotting. To prepare antibody beads, 
mouse anti-HA(12CA5), rat anti-HA(Roche), or rabbit anti-Gβ(1:300, Sigma) antibodies 
were cross-linked to Protein G or Protein A magnetic beads(New England Biolabs) 
following manufacturer’s protocols. The following antibodies were used for 
immunoblotting: rabbit anti-Gβ(Sigma), mouse anti-HA(12CA5), mouse anti-Myc 
(9E10), and rabbit anti-VSVG(Bethyl Laboratories). Anti-α-tubulin (DM1α, Sigma) was 
used as loading control. For co-immunoprecipitation from Xenopus egg extract, extract 
was diluted 10X with PBS, incubated with anti-Gβ beads, and beads processed as above. 
Eluted samples were immunoblotted using anti-Gβ and anti-GSK3(BD Transduction).  
 
Membrane protein isolation and detection of LRP6 
For membrane preparations, cells were incubated in media containing 0.6mM sodium 
vanadate in DMEM (without serum) for 3hrs. Cells were then lysed and membrane-
associated proteins isolated using ProteoExtract Native Membrane Protein Extraction 
kit(Calbiochem). To detect endogenous LRP6, endogenous phospho-LRP6, and 
transfected VSVG-LRP6, the following antibodies were used: rabbit anti-LRP6(Cell 
Signaling), rabbit anti-phospho-LRP6(Ser1490) (Cell Signaling), and rabbit anti-
VSVG(Bethyl Laboratories), respectively. 
 
In vitro protein binding assay 
For in vitro binding of Gβ1γ2 and GSK3, recombinant Gβ1γ2 was incubated with MBP or 
MBP-GSK3 protein in binding buffer (10mM HEPES pH 7.4, 300mM NaCl, 5mM 
MgCl2, 1mM EGTA, 0.1% Triton X-100, and 0.5mg/mL BSA) at 4˚C for 45mins. 
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Protein G magnetic beads(New England Biolabs) cross-linked to anti-MBP 
antibody(Sigma) were added and the reaction incubated at 4˚C for 45mins. Beads were 
washed 4X with binding buffer, 2X times with PBS, and samples were eluted and 
analyzed by immunoblotting. 
 
In vitro kinase assay 
Tau (200nM; r-Peptide, Tau-441) or LRP6ICD (100nM) were pre-incubated with 200nM 
or 400nM GSK3 (New England Biolabs), respectively, 200µM ATP, 20µCi [γ-32P]ATP, 
GSK3 kinase buffer (20mM HEPES pH 7.5, 300mM NaCl, 2 mM DTT, 1mM EDTA, 
10mM MgCl2, 0.2% Tween-20) and increasing concentrations of recombinant Gβ1γ2, Go, 
or BSA in a total reaction volume of 20µl. Samples were incubated at room temperature 
and aliquots removed at 30mins (Tau) or 15mins (LRP6ICD) for analysis by SDS-PAGE 
and autoradiography. 
 
Molecular modeling 
The software program MacPyMol was used to generate a model of the Gβ1γ2 
dimer(Protein Databank entry 1xhm) (Davis et al., 2005). 
 
Statistical analysis 
All luciferase assays were repeated atleast three times in triplicate. Values are presented 
as mean± standard deviation. We compared X by Analysis of Variance (ANOVA) to test 
the global hypothesis of equal mean intensities for all treatment conditions.  The global 
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hypothesis of all ANOVA analyses were rejected (p < 0.05).  All possible pairwise 
contrasts were evaluated using Tukey's HSD procedure.  
 
Results 
 
Biochemical screen identifies G proteins that regulate β-catenin turnover. 
The Xenopus egg extract system has been used to recapitulate numerous complex 
GTP-dependent phenomena such as microtubule dynamics, translation, DNA replication, 
nuclear envelope reformation, and mitotic spindle assembly (Blow et al., 1987; Gard and 
Kirschner, 1987; Kornbluth et al., 1994). It contains cytosol and other cellular 
components including plasma membrane, organelles, amino acids, and nucleotides at or 
near physiological levels (Ma et al., 1998). Furthermore, this system has been shown to 
recapitulate the regulation and degradation of exogenous, [35S]β-catenin via components 
of the Wnt pathway (Salic et al., 2000)(Figure 2.1). To assess whether Xenopus egg 
extract could be used to test the role of G proteins in β-catenin/TCF signaling, we used 
purified G protein heterotrimers (primarily Go) from brain tissue for reconstitution 
(Sternweis and Robishaw, 1984). We detected modest inhibition of [35S]β-catenin 
degradation upon addition of heterotrimer, with greater inhibition upon G protein 
activation by AlF4- (Figure 2.2A). Partial activity of the intact heterotrimer may have 
resulted from nucleotide exchange (GDP for GTP) of Go within these crude egg extract, 
which have been documented to contain high concentrations of GTP (Blow et al., 1987; 
Ma et al., 1998). 
To identify G proteins involved in β-catenin/TCF signaling, we tested the four 
major classes of Gα subunits for their capacity to inhibit degradation of [35S]β-catenin in 	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Figure 2.1: A schematic showing the preparation of Xenopus egg extract used for β-
catenin degradation and phosphorylation assays. Unfertilized Xenopus laevis eggs 
were collected from females stimulated to ovulate by injection with human gonadotropin, 
de-jellied, and extracts prepared with minor modifications. Briefly, de-jellied eggs were 
spun in a microcentrifuge at low speed (2,000 rpm for 2 min at 4˚ C) to remove excess 
buffer. Eggs were then crushed by centrifugation at high speed (15,000 rpm for 2 min at 
4˚ C), releasing their contents into the centrifuge tube. After the crushing spin, three 
layers of lysate could be readily observed: a dark pellet enriched in nuclei and pigments, 
a cytosolic layer, and a layer containing egg yolk and lipids. The cytosolic layer was 
removed and subjected to subsequent re-centrifugation (2-3X) at maximum speed. The 
final extract (~50-100 mg/ml) was used for all subsequent biochemical reconstitutions.  
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Figure 2.2: G proteins inhibit β-catenin degradation in Xenopus egg extract. (A) 
Addition of purified brain G protein (5 µM) inhibits degradation of radiolabeled in vitro 
translated (IVT) [35S]β-catenin in Xenopus egg extract and is potentiated by AlF4-. (B) 
Schematic of assay used to assess the effects of G protein subunits on IVT [35S]β-catenin 
degradation in Xenopus egg extract. (C) Table summarizing the activities of the major 
classes of G proteins subunits on IVT [35S]β-catenin turnover and phosphorylation of 
endogenous β-catenin by GSK3 in Xenopus egg extract. (D) Both recombinant Gβ1γ2 
(5µM) and brain Gβγ (5µM) inhibit β-catenin degradation. (E) Addition of brain 
Gβγ (5µM) to Xenopus egg extract inhibits phosphorylation of endogenous β-catenin at 
GSK3 target sites 33/37/41. Extract was analyzed after 2 hr incubation. Tubulin is 
loading control.  Figures are representative of experiments performed three times.  	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Xenopus egg extract (Figure 2.2B,C). The specificity of each G protein to inhibit [35S]β-
catenin turnover was further assessed by immunoblotting for endogenous β-catenin 
phosphorylation by GSK3 (Figure 2.2C; Figure 2.3). Both inactive (GDP-bound) and 
active forms were tested. For activation, proteins were bound to a GTPγS analog or 
treated with GDP-AlF4- (if nucleotide exchange is extremely slow in the absence of 
receptor as in the case of Gαt and Gαq).  We found that, in addition to the previously 
implicated Gαo and Gαq, Gαi2 inhibited exogenous β-catenin degradation and 
phosphorylation of endogenous β-catenin by GSK3 (Gao and Wang, 2007; Liu et al., 
2001; Katanaev et al., 2005; Liu et al., 2005; Najafi, 2009).  β-catenin was stabilized in 
extracts by the GDP-bound forms of Gαo and Gαi2 but not Gαq. This is likely due to 
dramatic differences in affinity for GTP and the rates of nucleotide exchange between Gα 
subunits (GDP dissociation rate of Gαo = 0.19 min-1 at 30o C; GDP dissociation rate of 
Gαi2 = 0.07 min-1 at 30o C; Gαq has very low affinity for GTP in the absence of receptor) 
(Hepler et al., 1993; Linder et al., 1990).  Interestingly, Gβγ protein purified from brain 
tissue and recombinant Gβ1γ2 inhibited β-catenin phosphorylation and degradation 
(Figure 2.2D,E; Figure 2.4). Additionally, Gβγ synergized with Gαο to inhibit β-catenin 
degradation, suggesting that Gαο and Gβγ act cooperatively (Figure 2.5A).  
We maintain that concentrations of Gα and Gβγ used in our assays are likely to be 
physiologically relevant. The effective concentrations of Gα and Gβγ in our biochemical 
assays are in the low micromolar range, well below the predicted concentrations of 
heterotrimeric G proteins at the plasma membrane (~1 mM) (Taussig et al., 1993). 
Furthermore, because membrane localization of G proteins is not homogeneous, local 
concentrations of G proteins within the plasma membrane may actually exceed 1 mM 	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Figure 2.3: Screen for heterotrimeric G protein subunits that inhibit β-catenin 
degradation and phosphorylation in Xenopus egg extract. (A) Degradation of in vitro-
translated [35S]β-catenin degradation in extract is inhibited upon addition of GαoA (1.0 
µM), Gαi2 (5.0 µM), or Gαq (0.5 µM). (B) Similarly, GαoA (1.0 µM), Gαi2 (5.0 µM), 
and Gαq (0.5 µM) each inhibit GSK3 phosphorylation of endogenous β-catenin in 
extracts as detected by a β-catenin phospho-33/37/41 antibody. All Gα preparations were 
estimated to be ~50-80% active based on nucleotide binding and/or fractional protection 
from trypsin proteolysis. Tubulin is loading control. Experiments were repeated at least 
four times with representative results shown. 
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Figure 2.4: Gβ1γ2 inhibits [35S]β-catenin degradation in a dose-dependent manner. 
Addition of increasing concentrations of Gβ1γ2  resulted in increased inhibition of          
β-catenin turnover in extracts. This experiment was repeated three times with 
representative results shown. 
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(Taussig et al., 1993).  Finally, there is a wide range of concentrations at which G protein 
subunits interact with specific effectors. For example, the interaction between Gαi and 
adenylylcyclase occurs at high nanomolar concentrations, whereas interaction between 
Gαi and K+ channels occurs at the picomolar concentrations (Breitwieser and Szabo, 
1988; Taussig et al., 1993).	  
 
Gβγ  binds and recruit GSK3 to the membrane. 
We hypothesize that the mechanism by which Gβγ inhibits β-catenin degradation 
in extract involves its sequestration of GSK3 into membranes, thereby preventing 
phosphorylation of cytoplasmic β-catenin. Isoprenylation of Gγ targets Gβγ subunits to 
the plasma membrane. Thus, Gβγ added to Xenopus egg extract (which contains 
membranous organelles) is likely incorporated into membranes. Furthermore, Gβγ has 
been previously shown to interact with three kinases, all of which are translocated to the 
membrane after binding Gβγ (Smrcka, 2008). In support of our hypothesis that Gβγ 
sequesters GSK3 into membranes, addition of GSK3 (but not Casein Kinase I) to extract 
reversed the inhibitory effects of Gβγ on β-catenin degradation (Figure 2.5B). 
Confirming an interaction between GSK3 and Gβγ, we next asked if Gβγ and GSK3 
could form a complex in Xenopus egg extract. In agreement with our hypothesis, we 
show that endogenous GSK3 co-immunoprecipitated with endogenous Gβγ from extract 
(Figure 2.5C). When co-expressed in cultured mammalian cells, GSK3 similarly co-
immunoprecipitated with Gβ1γ2 (Figure 2.5D). In contrast, we were unable to demonstrate 
co-immunoprecipitation of GSK3 and Gαο when both were co-expressed in cultured 
mammalian cells (data not shown). Finally, we observed interaction between  
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Figure 2.5: Gβ1γ2 binds and promotes GSK3 membrane localization. (A) Gβ1γ2 
synergizes with GαoA to inhibit β-catenin degradation. [35S]β-catenin was added to 
Xenopus egg extract and incubated with buffer, Gβ1γ2 (0.5µM), GαoA-GTPγS (0.25µM), 
or Gβ1γ2 (0.5µM) plus GαoA-GTPγS (0.25µM). (B) The ability of Gβ1γ2 to inhibit β-
catenin degradation in extract was reversed by addition of GSK3. [35S]β-catenin was 
added to extract and incubated with Gβ1γ2(5µM), Gβ1γ2 plus GSK3(10units/µl), or Gβ1γ2 
plus CKI (100units/µl). (C) GSK3 co-immunoprecipitates with Gβ from Xenopus egg 
extract. Anti-Gβ antibody beads were incubated with extract, washed, eluted with sample 
buffer, and immunoblotted for Gβ and GSK3. (D) GSK3 co-immunoprecipitates with 
Gβ1γ2 from cultured cells. HEK-293 cells were transfected with Myc-GSK3 and HA-
Gβ1γ2, lysed, HA-Gβ1γ2 immunoprecipitated, and Myc-GSK3 detected by 
immunoblotting. (E) GSK3 binds Gβ1γ2 in vitro. MBP-GSK3 (0.66µM) or MBP 
(0.66µM) was incubated with Gβ1γ2 (0.6µM) and immunoprecipitated with anti-MBP 
antibody. Samples were washed, eluted, and immunoblotted for Gβ and MBP. (F) Gβ1γ2 
enhances association of GSK3 with membrane fractions, and this effect is reversed by c-
βARK. HEK-293 cells were transfected with c-βARK, Myc-GSK3, and HA-Gβ1γ2. Cell 
membranes were isolated and immunoblotted for Myc and HA.  Data shown are 
representative of experiments performed at least three times.  
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purified Gβγ and GSK3 (Figure 2.5E). These results suggest that GSK3 and Gβγ directly 
interact. 
To test whether Gβγ binds GSK3 to promote membrane localization, we 
expressed Myc-GSK3 with or without HA-Gβ1γ2 in HeLa cells and isolated membrane-
associated proteins. An increased amount of GSK3 was membrane-associated when 
Gβ1γ2 was co-expressed (Figure 2.5F). Because cellular knockdown of Gβγ	   has been 
shown in previous studies to be complicated by subsequent loss of Gα signaling (Hwang 
et al., 2005; Krumins and Gilman, 2006). To circumvent this problem, we used the C-
terminal domain of β-adrenergic receptor kinase (c-βARK), which binds and inhibits free 
Gβγ (Koch et al., 1994). In support of our model, we found that inhibition of both HA-
Gβ1γ2 and endogenous Gβγ by c-βARK reduced membrane localization of Myc-GSK3 
(Figure 2.5F).  
 
Gβγ  is required for LRP6-stimulated β-catenin/TCF signaling. 
By promoting membrane localization of GSK3, Gβ1γ2 could enhance the activity 
of GSK3 towards its membrane substrates such as LRP6. HA-Gβ1γ2 expression resulted 
in a 2 to 5-fold enhancement of LRP6-stimulated TOPflash activity (a measure of β-
catenin/TCF transcriptional activation), which was blocked by c-βARK (Figure 2.6A, 
Figure 2.7A,B). Consistent with the importance of Gβ1γ2 membrane localization for its 
synergy with LRP6, overexpression of a Gγ2 CAAX mutant lacking the isoprenylation 
modification (required for Gγ membrane localization) dramatically reduced enhancement 
of LRP6-stimulated TOPflash activity (Figure 2.7C). Finally, c-βARK decreased  
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Figure 2.6: LRP6 activation of β-catenin/TCF signaling is regulated by Gβ1γ2. (A) 
Gβ1γ2 enhances LRP6 stimulation of TOPflash, and c-βARK inhibits the effects of Gβ1γ2 
on LRP6 activity. HEK-293 STF cells were transfected with various combinations of 
HA-Gβ1γ2, VSVG-LRP6, and c-βARK. Lysates were assayed by TOPflash and 
immunoblotting. *P=8.48x10-13,**P=3.35x10-12,***P=1.09x10-6 (ANOVA family-wise) 
(B) Scanning alanine mutagenesis of Gβ1 identifies amino acids that mediate LRP6 
activation. VSVG-LRP6 (40ng) was transfected alone or with the indicated Gβ1 mutant 
(50ng) plus Gγ2 (50ng) into HEK-293 STF cells. Lysates were assayed by TOPflash and 
immunoblotting (anti-HA for Gβ1 and anti-VSVG for LRP6). Red and white bars 
represent mutants that map to two clusters on the surface of Gβ1. For Topflash assays, 
experiments were performed in triplicate, and luciferase activity is fold-induction 
compared to LRP6 (mean ± s.d.). *P<0.005 (ANOVA family-wise). (C) The crystal 
coordinates of Gβ1γ2. Gβ1 is shown in teal and Gγ2 in gray. The seven β-propellers of Gβ 
are labeled B1-B7. Two clusters of amino acids required for Gβ1-enhanced LRP6 activity 
are in red and white. (D) Co-immunoprecipitation of GSK3 with Gβ1 point mutants. 
HEK-293 cells were transfected with Myc-GSK3, HA-Gβ1 point mutants, and Gγ2. Cells 
were lysed, HA-Gβ1 immunoprecipitated, and Myc-GSK3 detected by immunoblotting. 
Each experiment was repeated three times with representative results shown. 
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Figure 2.7: Gβ1γ2 enhancement of LRP6 stimulation of TOPflash is inhibited by 
inhibition of Gβγ  and loss of Gγ2 membrane localization. (A) Gβ1γ2 enhanced LRP6 	  
stimulation of TOPflash. HEK-293 STF cells (stably transfected with TOPflash, a 
luciferase-based β-catenin/TCF reporter) were transfected with HA-Gβ1γ2 and/or VSVG-
LRP6 and lysates assayed for luciferase activity. *P=0.0001 (ANOVA family-wise). (B) 
VSVG-LRP6 activation was inhibited by c-βARK. HEK-293 STF cells were transfected 
with VSVG-LRP6 plus increasing concentrations of c-βARK. Lysates were assayed by 
TOPflash and immunoblotting. *P=0.001, **P=9.94x10-6, ***P=3.41x10-7 (ANOVA 
family-wise). (C) Membrane localization of Gβ1γ2 is required for its capability to enhance 
LRP6 activity. In contrast to wild-type Gγ2, expression of a Gγ2 CAAX mutant (lacks 
signal for isoprenylation) did not enhance LRP6 activity as assessed by TOPflash. The 
amount of plasmid transfected is indicated. Luciferase activity is fold-induction 
compared to LRP6 (mean ± s.d.). Experiments were performed in triplicate.  
*P= 4.12x10-7, **P=6.81x10-7 (ANOVA family-wise). 
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TOPflash activation by LRP6 alone (Figure 2.6A, Figure 2.7B), suggesting that 
endogenous Gβγ contributed to LRP6 signaling. c-βARK  did not appear to exert its 
inhibitory effect by acting on other components of the β−catenin pathway, because we 
were unable to detect interaction of c-βARK with Axin, GSK3, or Dsh by co-
immunoprecipitation. Raising the possibility that c-βARK does not exert its effects on 
Wnt signaling through its interactions with known components of the pathway (data not 
shown).  
We did not observe any effects of HA-Gβ1γ2 on Wnt3a-stimulated activity in 
cultured cells (Figure 2.8A). This may suggest that, similar to CK1γ, Gβ1γ2 becomes 
limiting when LRP6 is present in excess (Davidson et al., 2005). c-βARK expression also 
had no effect on Wnt3a-stimulated activity (Figure 2.8B). One possibility is that Gβγ may 
signal through a distinct mechanism upstream of LRP6 (e.g. via non-Wnt3a-mediated 
pathways). Expression of c-βARK inhibited Dsh-stimulated activation (Figure 2.9A), 
indicating a requirement of Dsh for Gβγ. There was no detectable effect of HA-Gβ1γ2 or 
c-βARK when the pathway was stimulated by LiCl, a GSK3 inhibitor, confirming that 
Gβγ acts upstream of the β-catenin destruction complex (Figure 2.8C,D). These data 
suggest that Gβγ functions upstream of the destruction complex, at the level of LRP6 and 
Dsh. 
 
Identification of critical Gβ1 residues that mediate LRP6 activity and GSK3 
binding. 
 
Previous studies identified critical residues on Gβ1 that mediate its interaction 
with specific effectors (Ford et al., 1998; Scott et al., 2001). To determine whether these  
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Figure 2.8: Gβ1γ2 does not enhance activation by Wnt3a or LiCl treatment, and 
activation by Wnt3a or LiCl is not blocked by c-βARK. HEK-293 STF cells were 
transfected with HA-Gβ1 plus Gγ2 (A,C) or c-βARK (B,D) and treated overnight with 
Wnt3a-conditioned media (A,B) or 30 mM LiCl (C,D). Transfected cells were then lysed 
and processed for TOPflash. The amount of plasmid used for transfection is indicated. 
Luciferase activity is fold-induction compared to control (mean ± s.d.). Experiments were 
performed in triplicate. Statistical significant differences were not observed. 
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Figure 2.9: Dsh-mediated activation is inhibited by c-βARK. (A) HEK-293 STF cells 
were transfected with Myc-Dsh plus increasing concentrations of c-βARK. Transfected 
cells were then lysed and processed for TOPflash or immunoblotting. *P=3.85x10-5 
(ANOVA family-wise). (B) HEK-293 STF cells were transfected with HA-Gβ1 and Gγ2; 
Myc-Dsh; or HA-Gβ1, Gγ2 and Myc-Dsh. *P=8.94x10-5 (ANOVA family-wise). Lysates 
were assayed for TOPflash activity. The amount of each plasmid used for transfection is 
indicated. Luciferase activity is fold-induction compared to control (mean ± s.d.). 
Experiments were performed in triplicate.  
	   54 
sites also mediate GSK3 binding and/or LRP6 activation, we generated a series of single 
alanine mutants of Gβ1. We found that a subset of these Gβ1 mutants exhibited a 
decreased capacity to activate LRP6 (Figure 2.6B). Gβ is a WD40-repeat protein that 
forms a seven-bladed β-propeller structure (Smrcka, 2008). Based on previous X-ray 
crystal structures of Gβ, residues altered in this subset of mutants are clustered within 
two regions of Gβ1 (predominantly within blades 1, 3, and 4; Figure 2.6C). For the subset 
of Gβ1 mutants with impaired LRP6 activation, we next performed co-
immunoprecipitation experiments to test the capacity of each mutant to bind GSK3. 
Surprisingly, we found that several of these Gβ1 mutants bound GSK3 more avidly than 
wild-type Gβ1 (Figure 2.6D). These results support a model in which dynamic interaction 
between Gβγ and GSK3 is required to promote LRP6 activation. 
 
Gβγ  enhances GSK3 kinase activity towards LRP6. 
To further understand how Gβ1γ2 activates LRP6 signaling, we tested whether 
Gβ1γ2 enhances phosphorylation of LRP6 by GSK3. We transfected cells with Gβ1γ2 and 
GSK3, isolated membrane-associated proteins, and immunoblotted with an antibody that 
recognizes GSK3-phosphorylated sites on LRP6. When GSK3 was co-expressed with 
Gβ1γ2, there was an increase in phosphorylated LRP6 above that observed when GSK3 
was expressed alone (Figure 2.10A). LRP6 was also present in Gβ1γ2 
immunoprecipitates, suggesting that they form a complex (Figure 2.11B). Consistent with 
a recent study, we also detected Axin in Gβ1γ2 co-immunoprecipitates (Figure 2.11C) 
(Jung et al., 2009). Because c-βARK inhibits Dsh-stimulated activation, we tested 
whether Gβ1γ2 binds Dsh. Consistent with previous reports, we found that Dsh co- 
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Figure 2.10: Gβ1γ2 enhances phosphorylation of LRP6 by GSK3. (A) Gβ1γ2 increases 
phosphorylation of endogenous LRP6 when co-transfected with GSK3. HEK-293 cells 
were transfected with Myc-GSK3 with or without HA-Gβ1γ2 and lysates immunoblotted 
with anti-phospho-LRP6 (Ser1490). (B,C) Gβ1γ2 enhances GSK3 phosphorylation of Tau 
(B) and LRP6ICD (C) in vitro. Each experiment was repeated three times with 
representative results shown. 
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Figure 2.11: Dsh, Axin, and LRP6 form complexes with Gβ1γ2. (A) Dsh co-
immunoprecipitates with Gβ1γ2 from cultured cells. HEK-293 cells were transfected with 
HA-Gβ1 (1 µg), Gγ2 (1 µg), and Myc-Dsh (1 µg). Cells were lysed, HA-Gβ1 
immunoprecipitated, and Myc-Dsh detected by immunoblotting for the Myc tag. (B) 
LRP6 co-immunoprecipitates with Gβ1γ2 from cultured cells. Membrane proteins were 
isolated from HEK-293 cells transfected with HA-Gβ1 (1 µg), Gγ2 (1 µg), and VSVG-
LRP6 (1 µg). HA-Gβ1 was immunoprecipitated and VSVG-LRP6 detected by 
immunoblotting for the VSVG tag. (C) Axin co-immunoprecipitates with Gβ1γ2 from 
cultured cells. HEK-293 cells were transfected with HA-Gβ1 (1 µg), Gγ2 (1 µg), and Myc-
Axin (1 µg). Cells were lysed, Gβ1 immunoprecipitated, and Myc-Axin detected by 
immunoblotting for the Myc tag. Experiments were repeated at least three times with 
representative results shown. 	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immunoprecipitates with Gβ1γ2 (Figure 2.11A) (Angers et al., 2006; Jung et al., 2009; 
Egger-Adam and Katanaev, 2009). In summary, Gβγ appears to act in a complex with 
Dsh, Axin, and GSK3 to promote phosphorylation of LRP6. 
To determine if Gβγ directly affects GSK3 activity, we performed in vitro kinase 
assays. Gβγ enhanced GSK3 phosphorylation of Tau, a known GSK3 target, whereas 
undissociated heterotrimeric Go and BSA did not enhance GSK3 activity towards Tau 
(Figure 2.10B, Figure 2.12). Gβγ also enhanced GSK3 phosphorylation of the 
intracellular domain of LRP6 (LRP6ICD) on the PPPSP (Pro-Pro-Pro-Ser-Pro) motif, 
which has been shown to provide a docking site for Axin and is required for LRP6 
activity (Figure 2.10C, Figure 2.13). Interestingly, Gβγ stimulates GSK3 phosphorylation 
of LRP6ICD to a much lesser degree than for Tau (Figure 2.10C). This may reflect 
differences in the affinity of GSK3 for Tau versus LRP6ICD and a previously reported 
feedback mechanism by which phosphorylated LRP6 inhibits GSK3 activity (Cselenyi et 
al., 2008; Piao et al., 2008; Wu et al., 2009). Alternatively, LRP6 could simply compete 
with Gβγ for binding to GSK3. This latter model is consistent with our observation that 
Gβ1 mutants with increased affinity for GSK3 are unable to activate β-catenin/TCF 
signaling.  
 
Discussion 
GSK3 is the fourth identified Gβγ kinase effector (in addition to G protein 
coupled-receptor kinase 2, Bruton’s tyrosine kinase, and Phosphoinositide 3 kinase γ) 
(Smrcka, 2008). In each case, the mechanism of action of Gβγ appears to involve 
membrane translocation and, in the case of PI3Kγ, BTK, and GSK3, stimulation of kinase  
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Figure 2.12: Free Gβγ  is required for enhanced GSK3 activity towards Tau and 
LRP6ICD. Phosphorylation of Tau by GSK3 is enhanced by free Gβγ (A), but not by G 
protein heterotrimer purified from brain (B) or BSA (C). Experiments were repeated 
three times with representative results shown. 	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Figure 2.13: Phosphorylation of LRP6ICD by Gβγ-stimulated GSK3 occurs at the 
PPPSP Ser-1490 site as detected by immunoblotting. This experiment was repeated 
three times with representative results shown. 	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activity. It has recently been shown that regulation of GSK3 by Gβγ plays a critical role 
in controlling the stability of Snail, a GSK3 substrate, during zebrafish gastrulation 
(unpublished data, Speirs et al.). Thus, Gβγ may control diverse signaling pathways 
through regulation of GSK3. 
Gβ2γ2 has been reported to negatively regulate Wnt-1 signaling by a feedback 
mechanism that stimulates the degradation of Dsh (Jung et al., 2009).  Our results, 
however, are consistent with a recent study in Drosophila indicating that Gβγ acts to 
positively promote β-catenin/TCF signaling (Egger-Adam and Katanaev, 2009).  The 
simplest model to explain the activation of β-catenin/TCF signaling by Gβγ would 
invoke a receptor-mediated mechanism. In contrast to its effects on Dsh and LRP6, 
however, c-βARK did not inhibit Wnt3a activation of β-catenin/TCF signaling. One 
possibility is that receptor-mediated activation of the heterotrimer and subsequent 
association of Gβγ and GSK3 is a rapid and tightly coupled process. Indeed, there is 
evidence that certain GPCRs and their G proteins remain tightly associated upon 
activation by ligand (Gales et al., 2005). Thus, overexpression of c-βARK, which binds 
free Gβγ, may not be sufficient to disrupt Frizzled receptor-associated Gβγ. In support of 
a role for Gβγ in Wnt signaling, it has recently been shown that Drosophila Gβγ is 
required for proper activation of the Wnt pathway (Egger-Adam and Katanaev, 2009).	  
Alternatively, it is possible that signaling through Gβ1γ2 may be independent of 
Wnt/Frizzled. To date, Frizzled has not been demonstrated to be a bona fide GPCR; there 
is evidence, however, that traditional GPCRs can activate β-catenin/TCF signaling. 
Parathyroid receptor I has been reported to activate LRP6 to signal β-catenin/TCF-
mediated transcription, and the Gonadotropin releasing hormone receptor has been shown 
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to inhibit GSK3 activity and upregulation of β-catenin/TCF target genes (Gardner et al., 
2007; Wan et al., 2008). In the future, it will be important to distinguish whether Gβγ 
mediates β-catenin signaling via classic GPCRs or via Frizzled. 
We propose a model in which both Gα and Gβγ regulate β-catenin/TCF signaling 
(Figure 2.14). Our biochemical screen using purified recombinant proteins and Xenopus 
egg extract demonstrates a role for Gαo and Gαq, as well as Gαi2, in the inhibition of β-
catenin degradation. Additionally, our biochemical studies support a positive role for Gβγ 
in β-catenin/TCF signaling. Artificially tethering GSK3 to the plasma membrane is 
sufficient to stimulate Wnt signaling in cultured mammalian cells and axis duplication in 
Xenopus laevis embryos; thus, the β-catenin/TCF pathway appears to be very sensitive to 
GSK3 membrane localization (Zeng et al., 2005). Our data support a model in which Gβγ 
acts in concert with Dsh to recruit and activate GSK3 (either free or possibly in 
association with Axin) at the plasma membrane; membrane-associated GSK3 
phosphorylates LRP6, which binds to the β-catenin degradation complex to inhibit β-
catenin turnover. 
 
Future Directions 
 
Dissection of the nature of GSK3 and Gβγ  interaction 
 Our studies indicate that the interaction between Gβγ and GSK3 is direct.  Our 
mutagenesis analysis shows that the sites of interaction of GSK3 on Gβγ maps to the 
same interaction sites of known Gβγ effectors. We do not know how Gβγ enhances the 
kinase activity of GSK3. Mutagenesis of GSK3 may reveal specific sites of interaction on  
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Figure 2.14: Model for regulation of β-catenin/TCF signaling by Gα  and Gβγ .  
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GSK3 required for its interaction with Gβγ.  It would also be interesting and beneficial to 
understand at a structural level the nature of Gβγ’s activation of GSK3 kinase activity. 
Obtaining the crystal structure of Gβγ and GSK3 may reveal this information.  Both Gβγ 
and GSK3 have been crystallized and their structure has been solved (Dajani et al., 2001; 
Wall et al., 1995).  Additionally, we can take advantage of the 57A Gβ mutant, which has 
increased affinity for GSK3.  It is possible that Axin, LRP6 and or Dsh may be required 
to form a stable complex between Gβγ and GSK3 and these proteins may be required to 
assemble a protein complex that can be crystallized.   
 
Role of Gβγ  within current LRP6 signaling models 	   There are 2 current models for LRP6 signaling: the (1) initiation and amplification 
model (Baig-Lewis et al., 2007) and the (2) signalosome model (Bilic et al., 2007).   In 
the initiation and amplification model, Frizzled and LRP6 are required to receive the Wnt 
signal, and activation (and dimerization) of LRP6 is required for amplification of 
signaling.  Neither step alone can successfully transduce a Wnt signal such that both are 
required for robust signaling (Baig-Lewis et al., 2007).  In the signalosome model, Wnt 
stimulates Dishevelled and Axin polymerization and coaggregation of LRP6 with other 
Wnt signaling components.  This results in LRP6 phosphorylation (by CK1γ) and 
receptor activation (Bilic et al., 2007).  If Gβγ signals downstream of Wnt, it is possible 
that Gβγ fits in either of these models of LRP6 signaling. 
 In the initiation and amplification model, Gβγ may play roles both the initiation 
and amplification steps of the model. Signaling through Frizzled could result in the 
dissociation of Gα and Gβγ, allowing Gβγ to interact with and activate GSK3 at the 
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membrane resulting in the initial phosphorylation of LRP6 to initiate signaling.  This 
initial phosphorylation of LRP6 by GSK3 at LRP6’s PPPSP motifs could provide a 
docking site for Axin.  Because Gβγ can interact with Axin and Dishevelled, Gβγ may 
aid in the robust phosphorylation of LRP6 by the GSK3 on Axin and promote signal 
amplification (Angers et al., 2006; Jung et al., 2009; Egger-Adam and Katanaev, 2009). 
 As previously mentioned, Gβ can interact with multiple Wnt pathway 
components, including LRP6, GSK3, Axin, and Dishevelled (Angers et al., 2006; Jung et 
al., 2009; Egger-Adam and Katanaev, 2009).  In the signalosome model, all of these 
proteins are likely components of the signalosome.  Since Gβ can interact with each of 
these proteins, it is possible that Gβγ could also be part of the signalosome. Gβγ may 
stabilize the signalosome as well as promote LRP6 phosphorylation and activation. 
 
 
Role of Gβγ  signaling downstream of known GPCR 
Prostaglandin Receptor Signaling 
 Prostaglandin signaling is required for homeostasis and is involved in multiple 
physiological processes including digestion, reproduction, and immunity (Wang and 
Dubois, 2006).  Prostglandin E2 (PGE2) also plays a strong role in the promotion of 
cancer progression and is involved in tumor cell proliferation, invasion, angiogenesis, and 
immunosuppression in numerous tumor types, including colorectal, hepatocellular, and 
breast cancer (Wang and Dubois, 2006).  PGE2 is synthesized from arachidonic acid by 
cyclooxygenase (COX)-1 and -2 [also known as prostaglandin endoperoxide synthases 
(Ptgs)] producing PGC2 and PGH2.  PGH2 is then converted to PGE2 by Prostaglandin 
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E synthase (Ptges). PGE2 can signal by binding its G protein coupled receptor, E-
prostanoid (EP)1-4 (Regan, 2003; Wu, 2006) .   
Recent work by the Solnica Krezel lab has found that PGE2 signaling is required 
for cell movement during gastrulation in the developing zebrafish embryo (Speirs, 
unpublished). There was an increase in E-cadherin message and protein in embryos 
injected with a morpholino targeting ptges, which knocked down production of PGE2.  
This indicates that PGE2 signaling is linked to E-cadherin production (Speirs, 
unpublished).  Snail is a co-transcriptional repressor that binds the E-box of the E-
cadherin gene promoter to inhibit its expression (Barrallo-Gimeno and Nieto, 2005).  
Snail proteins levels can be regulated post-transcriptionally by phosphorylation (by 
GSK3) and its subsequent ubiquitination by β-TRCP and proteasomal degradation. Speirs 
et. al. found that levels of Snail were much lower in ptges morphants (lacking PGE2) 
compared to zebrafish embryos injected with nonsense morpholino suggesting that PGE2 
regulates E-cadherin levels by regulating Snail protein stability.  The PGE2 receptor is a 
GPCR and signaling by PGE2 acts in part through heterotrimeric G proteins. 
Overexpression of Gβγ subunits in the pgtes morphants blocks degradation of Snail 
indicating that Gβγ signals downstream of receptor activation to regulate Snail protein 
stability. In collaboration with the Drs. Speirs and Solnic Krezel, we have shown that in 
cell culture experiments Gβγ can interact with zebrafish GSK3, and that this interaction is 
enhanced in the presence of PGE2 (Speirs, unpublished).  This suggests that the 
interaction of Gβγ and GSK3 downstream of PGE2 stimulation stabilizes Snail protein 
and inhibits E-cadherin expression.  
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There are many connections between Wnt and PGE2 signaling. Axin2, a Wnt 
transcriptional target, has been shown to act as a nucleocytoplasmic chaperon for GSK3 
by binding GSK3 in the nucleus and exporting it into the cytoplasm, thereby stabilization 
Snail in the nucleus (Yook et al., 2006). In this way, Wnt/β-catenin transcriptional 
activation can stabilized Snail and reduce E-cadherin protein expression.  Snail has also 
been shown to activate β-catenin target gene expression by providing a positive feedback 
loop for Wnt dependent transcription; Snail can activate β-catenin target gene expression, 
inducing Axin2, which in turn helps to stabilize Snail by removing GSK3 form the 
nucleus (Stemmer et al., 2008). 
The involvement of Axin2 in Snail stabilization provides interesting insight into 
the mechanism of Gβγ inhibition of GSK3 phosphorylation on Snail.  Since we know that 
Gβγ  normally localizes to the membrane and we have found that Gβγ interacts with Axin 
it would be interesting to determine whether Axin2 plays a role in PGE2 signaling 
through Gβγ. Our studies indicate that Gβγ can enhance the kinase activity of GSK3, 
suggesting the possibility that additional GSK3 substrates are phosphorylated to regulate 
Snail stability.  One such GSK3 substrate is LRP6 and it is possible that LRP6 plays a 
role in PGE2 signaling. 
It is also possible that the Gβ mutants that bind GSK3 with a higher affinity 
would be better at stabilizing Snail in zebrafish embryos.  In addition, it would be 
interesting to see is c-βark can reverse the Snail rescue by Gβγ in the ptges morphants. 
Because PGE2 signaling enhances the association of Gβγ and GSK3 in culture cells, 
GSK3 may localize to the plasma membrane after PGE2 signaling in embryos.  
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Parathyroid Receptor Signaling 
The parathyroid hormone (PTH) is a hormone that targets bone, kidney, and 
intestine, and acts to regulate calcium metabolism (Jilka, 2007; Potts and Gardella, 2007).  
PTH signals by binding the Parathyroid hormone 1 receptor (PTH1R) which activates 
Gαs, Gαq, and Gβγ resulting in the production of 3’,5’-cyclic adenosine-5’-
monophosphate (cAMP), and subsequent activation of protein kinase A (PKA) (Abou-
Samra et al., 1991; Juppner et al., 1991).  Although it is thought that the PKA signals to 
mediate the PTH response, the exact molecular mechanism is not known. 
Wnt signaling is also essential for skeletal biology and recently a link between 
bone mass and gain of loss of function of LRP5 and the Wnt antagonist sclerostin was 
identified (Baron et al., 2006; Balemans and Van Hul, 2007; Glass and Karsenty, 2007).  
Additionally, PTH activates β-catenin signaling in osteoblasts by signaling through the 
Wnt co-receptor LRP6 (Wan et al., 2008). As with treatment with Wnt3a, PTH treatment 
of cells expressing the PTH1R receptor stimulated TOPflash activity and stabilized 
cytoplasmic β-catenin. PTH also stimulated PTH-PTH1R-LRP6 complex formation, 
LRP6 phosphorylation, and membrane recruitment of Axin. Furthermore chemical 
inhibition of PKA with H89 inhibited PTH stimulated TOPflash, but not stimulation by 
Wnt3a, suggesting that Wnt3a and PTH may signal through similar but not identical 
downstream signaling events (Wan et al., 2008).  
In addition to the endocrine factor PTH, PTH1R signals through the 
paracrine/autocrine factor PTHrR (Parathyroid hormone related protein) (Kronenberg et 
al., 1996).  Although PTH1R signals through functionally distinct ligands, there is only 
one isoform of the receptor.  This one isoform of PTH1R has been shown to signal 
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through multiple subclasses of Gα subunits including Gαs, Gαq/11, Gαi/o, and 
Gα12/13, and has been linked to multiple signaling pathways (Abou-Samra et al., 1991; 
Bringhurst et al., 1993; Cheung et al., 2005; Offermanns et al., 1996).  This indicates that 
PTH1R can promiscuously interact with multiple heterotrimeric G proteins. One 
explanation for this receptor’s promiscuity is that the receptor interacts with Gβγ directly 
such that Gβγ links the receptor to the Gα subunits.  Structure function analysis identified 
specific sites within the c-terminal tail of PTH1R that is required for high affinity 
interaction with Gβγ and for Gα signaling (Mahon et al., 2006).  Structural analysis (by 
X-ray crystallography) of Gβγ bound to the C-terminal tail of PTH1R indicates that the 
regions of predicted membrane-facing region of Gβ is oriented to the membrane spanning 
receptor, and the region of interaction is highly conserved for isoforms 1-4 of Gβ 
(Johnston et al., 2008). This suggests that the interaction of PTH1R with Gβγ may 
explain PTH1R’s promiscuity as well as provide a mechanism for receptor mediated Gα 
activation (Johnston et al., 2008).   
 Since PTH1R binds Gβγ and can complex with and activate LRP6, it would be 
interesting to know if PTH1R signals through Gβγ interaction with GSK3.  If this is the 
case, one would expect that PTH treatment might enhance the interaction of Gβγ and 
GSK3. Overexpression of Gβγ along with PTH treatment might also enhance TOPflash 
activation and c-βark expression may inhibit signaling.  It is possible that over-expression 
of Gβγ could enhance PTH stimulated phosphorylation of LRP6 and expression of the 
Gβγ inhibitor c-βark could decrease PTH stimulated LRP6 phosphorylation. This would 
provide further evidence that Gβγ-GSK3 interaction can signal downstream of numerous 
GPCRs. 
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Wnt signaling components as bona fide G protein signaling proteins 
Axin 
The scaffold protein Axin contains a RGS (regulator of G protein signaling) 
domain, a conserved domain that acts as a GTPase activating protein (GAP) by binding a 
Gα subunit unit when bound to GTP, stabilizing the GTP hydrolysis transition state, and 
enhancing the rate of GTPase hydrolysis.  This decreases the amount of time that the Gα 
subunit is bound to GTP and active.  The RGS domains may not have GAP activity and 
instead limit Gα-GTP activity by binding the Gα and inhibiting it from interacting with 
effectors. Mutagenesis analysis revealed that Axin’s RGS domain is also the site of its 
interaction is APC, the other scaffold protein required for destruction complex formation 
and function (Behrens et al., 1998; Hart et al., 1998; Kishida et al., 1998).  Structural 
analysis found that APC localizes to the opposite face of the RGS domain from the G 
protein binding site.  This suggests that Axin may be able to interact with APC and Gα 
proteins at the same time and that Axin’s interaction with APC does not inhibit it from 
interacting with Gα as well.  Axin’s RGS domain appears to lack GTPase activity, 
although it interacts with various Gα subunits including Gαo, Gαs, and Gα12 
(Castellone et al., 2005; Egger-Adam and Katanaev, 2009; Stemmle et al., 2006). There 
are no reports, however, that demonstrate that Axin’s RGS domain has GAP activity.  
Unpublished preliminary data from Dr. Elliott Ross’ lab  (UT Southwestern) suggests 
that Axin contains a low level of GTPase activity.  Mutational analysis of Axin’s RGS 
domain followed by GTPase assays may provide insight into whether or not Axin’s RGS 
domain contains GAP activity. 
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Because Gαo and Axin interact through Axin’s RGS domain, we could also 
express and purify Gαo and Axin (or a fragment of Axin containing its RGS domain) in a 
complex, and perform structural analysis to directly identify the nature of this interaction.   
 
Frizzled 
Although there is a body of evidence that suggests that Frizzled is a GPCR, it has 
not been directly demonstrated that Frizzled signals through heterotrimeric G proteins.  A 
preliminary manuscript from Nature Proceedings reports that Frizzled containing 
bacterial membranes interacts with Gαo in a pertussis toxin sensitive manner, and can 
activate Gαo nucleotide exchange after treatment with Wnts (Katanaev and Buestorf1, 
2009). This Wnt stimulated activation of Gαo nucleotide exchange is also sensitive to 
inhibition by secreted Fz-related proteins (sFRP).  Although this report has not been peer 
reviewed, this is the first reported attempt to demonstrate that Fz is a bona fide GPCR.   
There are a number of issues with this report.  First of all, the biochemical assays 
were conducted with partially purified components.  The Frizzled receptor was expressed 
in E.coli cells then membranes were isolated.  The Frizzled proteins was never isolated 
from the bacterial membrane, so there could have been contribution by the E.coli protein 
in the membrane protein prep.  Also, they saw a bell shaped response in their guanine 
nucleotide binding assay such that at low and high concentrations of Wnt ligand they saw 
only low levels of nucleotide exchange.  They attributed this to inhibitor action of carrier 
proteins within the Wnt preparation.  The use of purified Wnt3a ligand should be able to 
resolve this issue of carrier proteins.   
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Altogether, the data reported was rather weak, however it does provide a 
foundation for others to more definitely illustrate a role for Frizzled as a functional 
GPCR.  
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The work described in this chapter has been published  
(Cselenyi CS, Jernigan KK et al., 2008) 	  	  	  	  
Introduction 
The best-characterized form of Wnt signaling is the Wnt/β-catenin, or canonical 
Wnt, pathway (Logan and Nusse, 2004). During Wnt/β-catenin signaling, a Wnt ligand 
binds transmembrane coreceptors Frizzled (Fz) and low-density lipoprotein receptor-
related proteins 5 or 6 (LRP5/6) and initiates a process that leads to stabilization and 
nuclear translocation of β-catenin. In the nucleus, β-catenin binds transcription factors of 
the T cell factor/lymphoid enhancer factor (TCF/LEF) family and activates a Wnt/β-
catenin transcriptional program.  Although the mechanism by which a Wnt ligand 
mediates β-catenin stabilization is poorly understood, regulation of β-catenin levels in the 
absence of Wnt signaling has been well characterized. In the absence of a Wnt ligand, β-
catenin is marked for degradation through its interaction with a destruction complex 
consisting of two scaffold proteins, Axin and adenomatous polyposis coli protein (APC), 
and two kinases, glycogen synthase kinase 3 (GSK3) and casein kinase 1α (CK1 α) 
(Logan and Nusse, 2004). CK1 α phosphorylation of β-catenin primes it for subsequent 
phosphorylation by GSK3, which targets β-catenin for ubiquitin-mediated proteolysis 
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(Logan and Nusse, 2004). It is hypothesized that Wnt signal transduction stabilizes β-
catenin by inhibiting destruction complex formation or activity.   
The Wnt coreceptor LRP5/6 is required for Wnt/β-catenin signaling (Pinson et al., 
2000; Tamai et al., 2000; Wehrli et al., 2000). Although LRP6 is more potent than LRP5 
in certain assays, experiments have not revealed qualitative differences in their 
mechanisms of action (Mi and Johnson, 2005). Wnt signaling through LRP5/6 is 
proposed to inhibit destruction complex formation by promoting degradation of the 
destruction complex scaffold Axin. LRP5 overexpression was initially shown to promote 
Axin degradation in cultured mammalian cells (Mao et al., 2001b). Genetic studies in 
Drosophila indicate that activation of the Wnt pathway by Arrow, the LRP5/6 ortholog, 
decreases steady-state Axin levels (Tolwinski et al., 2003). Wnt signaling through LRP6 
also promotes degradation of endogenous Axin in Xenopus oocytes and embryos (Kofron 
et al., 2007). Because the concentration of Axin is significantly lower than that of other 
destruction complex components, reduction of Axin levels represents a potentially robust 
mechanism for β-catenin stabilization (Lee et al., 2003). As a result, LRP5/6-mediated 
Axin degradation is proposed to be a critical event in transduction of a Wnt signal 
(Tolwinski and Wieschaus, 2004).  Although there is strong evidence that signaling by 
LRP5/6 reduces Axin levels, Wnt-mediated stabilization of β-catenin in cultured 
mammalian cells occurs ≈2 h before substantial changes in Axin levels are detected 
(Willert et al., 1999; Liu et al., 2005). These data suggest that Axin degradation may not 
be required for initial signal transmission; alternatively, turnover of a small, localized 
pool of Axin may be necessary for signaling but may be undetected in these experiments. 
Such a mechanism has been described for β-catenin: the vast majority of β-catenin is 
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associated with cadherins at cellular membranes, and only the small, cytoplasmic pool of 
β-catenin protein is stabilized in response to Wnt signaling (Heasman et al., 1994; Peifer 
et al., 1994). Here, we address whether LRP6 can stabilize β-catenin independently of 
Axin degradation. We reconstituted LRP6 signaling in biochemically tractable Xenopus 
egg extract, which has been used to accurately reconstitute cytoplasmic aspects of Wnt 
signal transduction (Salic et al., 2000; Lee et al., 2001; Major et al., 2007). We find that 
LRP6 can promote β-catenin stabilization in the absence of Axin degradation by directly 
inhibiting GSK3's phosphorylation of β-catenin. 
  
Methods 
 
Plasmids and Recombinant Proteins.  
 Axin truncation mutants were made by PCR from full length, Myc-tagged mouse 
Ax in and subcloned in pCS2. AxinΔ298–437 and AxinΔ437–506 have been previously 
described (Logan and Nusse, 2004). AxinSA harbors Ser-Ala mutations at the following 
predicted GSK3 phosphorylation sites: SANDSEQQSLS. We refer to mouse Ax in 
(GenBank Accession: XM914907) amino acid (aa) 126 as ‘‘start methionine’’ 
(CSLMQSP). Mouse and human LRP6ICD (aa 1397–1614) (GenBank Accessions: 
NM008514 and NM002336, respectively) were subcloned into pET11-D or pCS2 using a 
PCR-based approach. For Lrp6ICD mRNA (SI Figure 3.3C only), the intracellular 
domain of mouse LRP6 with an N-terminal myristoylation target sequence was 
engineered into pCS2. For BiFC, YN (YFP1–154), YC (YFP155–238) , LRP6I CD with 
a N-myristoylation sequence, and human β-catenin were cloned into pCS2. Fusions for 
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BiFC were separated by a Ser-Gly-Gly-Gly-Gly-Ser linker. All oligonucleotide primer 
sequences are available upon request. For LRP6ICD purification, BL21 cells harboring 
LRP6ICD- pET11-D were grown to OD600 of 0.3 at 37°C and induced with isopropyl-
D-thiogalactoside (IPTG) (0.3 µg/ml) for 9 h. Induced bacteria were harvested, and 
protein was purified on Nickel NTA-beads (Qiagen). Eluted protein was concentrated to 
1 mg/ml, flash-frozen, and stored at 80°C. For GST-ubiquitin purification, protein was 
expressed and purified as above but induced with IPTG (1µg/ml) for 4 h and purified on 
glutathione resin.  
  
mRNA Synthesis and RT-PCR.  
 Capped RNA for embryo injection was synthesized from linearized plasmid DNA 
templates by using mMessage mMachine (Ambion). Animal caps were cut from stage 9 
embryos and cultured in 75% Marc’s modified Ringers (MMR) [0.1 M NaCl, 2 mM KCl, 
1 mM MgSO4, 2 mM CaCl2, 5 mM Hepes (pH 7.4)] until stage 11. RT-PCR for siamois, 
Xnr3, and ODC were performed by using primers and conditions previously described 
(www. hhmi.ucla.edu/derobertis/index.html).  
  
Tau Phosphorylation.  
 Recombinant Tau (rPeptide, Tau-441) was added to egg extract (40 µg/ml) 
supplemented with GSK3 (NEB) (5 µg/ml). After 2 h incubation at RT, extracts were 
immunoblotted.  
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Xenopus Egg Extract Degradation Assay and Depletion.  
 Xenopus egg extract was prepared and degradation assays were per for med as 
described (Logan and Nusse, 2004).  Extract was incubated with LRP6ICD at a 
concentration of 1.6 µM unless other wise noted. In Axin-depletion experiments, IVT 
proteins were made in wheat germ lysate (Promega). Dsh and Ax in immunodepletions 
were performed and confirmed as described (Logan and Nusse, 2004), with 
modifications. Xenopus egg extract was incubated with an equal volume of Protein A- 
Affiprep beads (BioRad) bound to either Dsh or Axin polyclonal antibodies. Incubation 
was performed at 4°C for 2 h with inversion every 10 min. As shown in Figure 3.6D, 
Axin antibody was covalently conjugated to Protein A magnetic beads (NEB) for 
depletion.  
  
Phosphatase Treament.  
 Samples (0.8 µl) from a Xenopus egg extract degradation assay were added to λ−
phosphatase buffer (12.5 µl) and 400 units of λ−phosphatase (NEB), incubated for 30 
min at 30°C, and then diluted in sample buffer. Samples were then processed for 
SDS/PAGE and autoradiography.  
  
Ubiquitination Assay.  
 Radiolabeled, IVT Axin (1 µl) was incubated at RT with 17.5 µl egg extract 
supplemented with GST-ubiquitin (50 µg/ml) in the presence or absence of LRP6ICD. At 
indicated times, the reaction was diluted with 100 µl Buffer A [50 mM Tris (pH 8), 200 
mM NaCl, 0.1% Tween-20, and 0.1 mM PMSF] and applied to 5 µl glutathione-
	   77 
Sepharose beads. After 2 h shaking at 4°C, the beads were washed with 3 ml Buffer A, 1 
ml Buffer B [50 mM Tris (pH 8), 50 mM NaCl, and 0.1 mM PMSF], and eluted with 
sample buffer and analyzed by SDS/ PAGE and autoradiography. 
  
Trypsin Digest.  
 Xenopus egg extract (3 µl) was incubated with IVT, radioloabeled Axin (0.5 µl) 
and GSK3 (15 µg/ml) for 30 min. Bovine pancreatic trypsin (0.38 mg/ml) (Sigma) was 
added and samples were incubated at RT for 80 sec. Soybean trypsin inhibitor (0.8 
mg/ml) (Sigma) and sample buffer were then added for analysis by SDS/PAGE and 
autoradiography. 
  
Axin/LRP6ICD Binding Assay.  
 For Axin pull down, nickel-NTA beads (10 µl) (Qiagen); LRP6ICD (10 µg); egg 
extract (20 µl); and radiolabeled, wheat germ IVT Axin (2 µl) were combined. Sample 
volume was adjusted to 40 µl with Buffer A, and samples were incubated at RT for 30 
min. Buffer A (200 µl) was then added followed by 2 h shaking at 4°C. Beads were 
washed with 9 ml Buffer A, and protein was eluted from beads with sample buffer and 
analyzed by SDS/PAGE and autoradiography. 
  
mRNA Synthesis and RT-PCR.  
 Capped RNA for embryo injection was synthesized from linearized plasmid DNA 
templates by using Immunoprecipitation (IP). For IP, egg extract (50 µl) was incubated 
with or without LRP6ICD and IVT β-catenin (3 µl) for 2 h. Buffer A (700 µl) was added 
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to extract with Protein A beads covalently conjugated to myc or Axin antibody followed 
by 2 h shaking at 4°C. Beads were washed with Buffer A (4 ml), eluted with sample 
buffer, and analyzed by SDS/PAGE and immuno-blot.  
  
Kinase Assay.  
 LRP6ICD or LRP6ICD(PPPAPX5) (4.1 µM), MBP-Axin (0.1 µM) , GSK3 (0.79 
µM) (NEB), and CK1 (1.37µM) (NEB) were preincubated with 500 µM ATP and kinase 
buffer [20 mM Hepes (pH 7.5), 300 mM NaCl, 2 mM DTT, 1 mM EDTA, 10 mM 
MgCl2, and 0.2% Tween 20] for 10 min at RT. His6-β-catenin (0.22 µM) and Tau (0.34 
µM) (rPeptide Tau-441) were then added and samples were removed for immunoblotting 
after 45 min at RT. 
  
Immunoblotting  
 Proteins were separated by SDS/PAGE, transferred to nitrocellulose membranes, 
and immunoblotted. Bands were visualized by using horseradish peroxidase-conjugated 
secondary antibodies and SuperSignal West Pico or Fempto Chemiluminescent Substrate 
(Pierce). For reblotting, membranes were stripped by incubation in (0.4 M) for 15 min 
followed by 15 min in H2O and reblocking. α-Tubulin was blotted with DM1α (Sigma) 
(1:5,000 dilution). β-catenin P33/37/41 antibody was purchased from Cell Signaling 
Technology (1:1,000 kinase assay; 1:250 egg extract). β-catenin P45 antibody was 
purchased from Cell Signaling Technology (1:500). N-terminal Xenopus β-catenin 
antibody was a generous gift from Barry Gumbiner (1:3,000). Antibodies for Axin 
immunodepletion and immuno-precipitation were described previously. Axin antibody 
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for immunoblot was purchased from R & D (anti-human/mouse/rat Axin 1) (1:100). 
Antibodies to Dsh were described previously (1:100). GSK3 was blotted with IH8 
(Affinity Bioreagents) (1:500). His6 tag was blotted with the MCA1396 antibody 
(Serotec). Phospho-LRP6 (Ser-1490) was purchased from Cell Signaling Technology 
(1:500). Myc was blotted with 9E10 (Sigma) (1:500). Total Tau was blotted with T-
1308–1 (rPeptide) (1:15,000). Antibody to Tau P396 was purchased from Cell Signaling 
Technology (1:500).  
  
Cell Culture, Transfection, and Bimolecular Fluorescence Complementation (BiFC).  
 HEK293 cells were transfected with Lipofectamine 2000 (Invitrogen) and 
maintained in Dulbecco’s modified essential medium (DMEM) supplemented with 10% 
FBS and antibiotics. Cells were grown at 37°C in 5% CO2 for 24 h and then incubated at 
30°C for 20 h. Cells were fixed at RT for 20 min on fibronectin-coated coverslips with 
4% formaldehyde in CB buffer [10 mM Mes (pH 6.1), 138 mM KCl, 3 mM MgCl2, 2 
mM EGTA] supplemented with 11.66% wt/vol sucrose. Slides were mounted with 
VectorShield containing DAPI stain and imaged by using a Nikon Eclipse 80i 
fluorescence microscope with a Nikon 60A objective and a Cool Snap ES camera. YFP 
signal was measured by excitation at 515 nm and emission at 555 nm. All images were 
taken under identical settings.  
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Results 
 
Recombinant LRP6 intracellular domain protein activates Wnt/β-Catenin signaling 
in Xenopus embryos. 
 
LRP5/6 is a single-span transmembrane Wnt coreceptor. Expression of the 
LRP5/6 intracellular domain in cultured mammalian cells accurately recapitulates 
LRP5/6 signal transduction, promoting β-catenin stabilization and regulating Wnt/β-
catenin target gene expression (Mi et al., 2006; Mi and Johnson, 2005, 2007). To obtain 
soluble LRP6 for analysis in biochemically tractable Xenopus egg extract, we bacterially 
expressed and purified recombinant polypeptide encoding the LRP6 intracellular domain 
without its transmembrane domain (LRP6ICD; Figure 3.1A,B).  
We first tested whether LRP6ICD activates Wnt/β-catenin signaling in vivo. 
Ventral injection of LRP6ICD protein into Xenopus embryos at a concentration similar to 
that of other pathway components (Lee et al., 2003) induces complete axis duplication 
and promotes transcription of Wnt/β-catenin targets, siamois and Xnr3, in ectodermal 
explants (Figure 3.1C,D).  Our results provide phenotypic and transcriptional evidence 
that recombinant LRP6ICD protein purified from bacteria promotes Wnt/β-catenin 
signaling in vivo.  
  
LRP6ICD promotes β-Catenin stabilization and Axin degradation in Xenopus egg 
extract. 
 
To establish a cell-free system that would facilitate biochemical analysis of LRP6 
signaling, we tested whether recombinant LRP6ICD, which activates Wnt signaling in 
vivo, prevents degradation of β-catenin in Xenopus egg extract. We find that LRP6ICD  
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Figure 3.1: Recombinant LRP6ICD activates Wnt signaling in vivo and in Xenopus 
egg extract.  (A)  LRP6ICD spans the intracellular domain of mouse LRP6 (aa1397-
1614) and does not include its transmembrane domain.  ECD, extracellular domain; ICD, 
intracellular domain; TM, transmembrane domain; HT, 6Xhistidine tag.  (B)  Coomassie-
stained gel of recombinant LRP6ICD (1 µg) purified from bacteria. (C)  Injection of 
LRP6ICD protein (33 nM) into each ventral blastomere of 4-cell Xenopus embryos 
promotes development of a complete ectopic axis (bottom left panel, embryo side view; 
bottom right panel, embryo ventral view) in 73% of embryos (n=15).  A lower dose of 
LRP6ICD protein (20 nM) promotes axis duplication in 46% of embryos (n=15). (D)  
Injection of LRP6ICD (33 nM) at the 4-cell stage promotes ectopic transcription of Wnt/ 
β-catenin targets Xnr3 and siamois in animal caps as assayed by RT-PCR.  WE, whole 
embryos; Caps, animal caps; WE-RT, no reverse transcriptase added; ODC, ornithine 
decarboxylase (loading control). (E)  Addition of LRP6ICD (1.6 µM) to Xenopus egg 
extract prevents degradation of radiolabeled, IVT β-catenin and promotes degradation of 
radiolabeled, IVT Axin and Axin2. (F)  Unlike LRP6ICD, LRP6ICD(PPPAPX5) (1.6 
µM) does not inhibit β-catenin degradation or promote Axin degradation.  (G)  LRP6ICD 
promotes a reduced mobility of IVT, radiolabeled Axin on SDS-PAGE in addition to 
Axin degradation.   Treatment with λ-phosphatase reverses the LRP6ICD-induced Axin 
mobility shift. 
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protein prevents degradation of radiolabeled, in vitro-translated (IVT) β-catenin in 
Xenopus egg extract (Figure 3.1E). Consistent with a proposed mechanism for LRP6  
signaling, we demonstrate that LRP6ICD also stimulates degradation of IVT Axin and 
Axin2 (Figure 3.1E). We also tested whether LRP6ICD induces phosphorylation of Axin. 
We find that λ-phosphatase reverses the LRP6ICD-mediated upward mobility shift of the 
Axin protein detected by SDS/PAGE, suggesting that LRP6ICD promotes Axin 
phosphorylation (Figure 3.1G). However, in the presence of LRP6ICD, the total Axin 
signal is decreased even after λ-phosphatase treatment, consistent with LRP6ICD 
mediating Axin degradation.  
The ability of LRP6 to stabilize β-catenin depends on GSK3's phosphorylation of 
the serine residue on at least one of five Pro-Pro-Pro-Ser-Pro (PPPSP) motifs on LRP6 
(Tamai et al., 2004) (Zeng et al., 2005). If LRP6ICD accurately reconstitutes endogenous 
LRP6 signaling in extract, LRP6ICD's activity should depend on intact PPPSP motifs. An 
LRP6 construct in which all five PPPSP motifs have been mutated to PPPAP (PPPAPX5) 
does not bind Axin or stabilize β-catenin in cultured cells (Tamai et al., 2004). This 
construct also fails to activate Wnt target genes in Xenopus ectodermal explants (Tamai 
et al., 2004). To test whether LRP6ICD signaling in egg extract requires intact PPPSP 
motifs, we expressed and purified LRP6ICD(PPPAPX5) protein from bacteria. In 
contrast to LRP6ICD, LRP6ICD(PPPAPX5) does not inhibit β-catenin degradation or 
stimulate Axin degradation in egg extract (Figure 3.1F), even when added at a 
concentration 2-fold higher than that used for LRP6ICD (data not shown). We also find 
that LRP6ICD, but not LRP6ICD (PPPAPX5), is phosphorylated at PPPSP Ser-1490 in 
egg extract (Tamai et al., 2004; Zeng et al., 2005) (Figure 3.6C). Requirement of these 
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PPPSP motifs suggests LRP6ICD in extract functions in a manner that is similar to that 
of LRP6 in cultured cells and Xenopus embryos.  
  
LRP6ICD signals independently of Disheveled in Xenopus egg extract and embryos. 
 
Disheveled (Dsh) is a cytoplasmic protein required for signaling downstream of 
Fz and upstream of the β-catenin destruction complex (Logan and Nusse, 2004).  In 
cultured mammalian cells, overexpression of LRP6 that lacks its extracellular domain 
promotes Wnt signaling despite down-regulation of Dsh by RNAi or overexpression of a 
dominant-negative form of Dsh (Li et al., 2002), suggesting that the intracellular domain 
of LRP6 can signal independently of Dsh. More recently, it was shown that Dsh is 
required for LRP6 oligomerization and phosphorylation (Bilic et al., 2007), which are 
necessary for LRP6-mediated activation of Wnt/β-catenin signaling. Interestingly, LRP6 
expressed without its extracellular domain bypasses this requirement for Dsh and is 
constitutively oligomerized and phosphorylated (Bilic et al., 2007). These data suggest 
that LRP6ICD may mimic Dsh-activated LRP6 and circumvent the requirement for Dsh 
in Wnt/β-catenin signaling.  
To test whether LRP6ICD signaling in Xenopus egg extract bypasses its 
requirement for Dsh, we immunodepleted endogenous Dsh from egg extract (Salic et al., 
2000). Depletion of Dsh (Figure 3.2A) did not affect the ability of LRP6ICD to stabilize 
β-catenin or promote Axin degradation (Figure 3.2B).  To determine whether Dsh is 
required for LRP6ICD signaling in vivo, we tested whether Xdd1 (a dominant negative 
form of Dsh) (Sokol, 1996) prevents LRP6's activation of the Wnt/β-catenin pathway in 
Xenopus embryos. In mRNA coinjection experiments, Xdd1 inhibits Wnt8-induced  
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Figure 3.2: LRP6ICD signals independently of Dsh in Xenopus egg extract and 
embryos.  (A)  Immunoblot of Dsh-depleted and mock-depleted (Protein A beads) egg 
extract.  (B)  Dsh depletion does not affect the ability of LRP6ICD to promote β-catenin 
stabilization or Axin degradation in egg extract.  (C)  To compare Xdd1 mRNA-mediated 
suppression of Xwnt8 mRNA-induced and LRP6ICD mRNA-induced axis duplication, 
mRNAs were titrated to promote axis duplication in 50-60% of injected embryos.   
Dominant negative Dsh (Xdd1) (1 ng RNA) prevents axis duplication by Wnt8 (1pg 
RNA) but not by LRP6ICD (500 pg).  For duplication assays, Xenopus embryos were 
injected in each ventral blastomere at the 4-cell stage.  
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secondary axis formation but has no effect on the ability of LRP6ICD to induce 
secondary axes (Figure 3.2C). Thus, our data in Xenopus egg extract and embryos 
demonstrate that LRP6ICD signals independently of Dsh and are consistent with a model 
in which LRP6ICD mimics Dsh-activated LRP6 in Wnt/β-catenin signaling (Bilic et al., 
2007). 
Axin-bound GSK3 has been suggested to play a role in phosphorylation and 
activation of LRP6 (Zeng et al., 2008). Because phosphorylation of LRP6 is a 
prerequisite for its binding to Axin (Tamai et al., 2004), however, the initial 
phosphorylation of LRP6 may occur by a pool of GSK3 that is not bound to Axin. In egg 
extract where Axin has been immunodepleted, we find that LRP6ICD still becomes 
phosphorylated at PPPSP Ser 1490 as assayed by immunoblot (data not shown), 
suggesting that initial LRP6 phosphorylation may occur independently of Axin.  
  
LRP6ICD-mediated Axin degradation occurs via the ubiquitin/proteasome pathway 
and is distinct from GSK3-regulated Axin degradation. 
 
To identify the mechanism by which LRP6 promotes Axin degradation, we tested 
whether LRP6ICD induces Axin degradation via an ubiquitin-mediated, proteasome-
dependent process. We find that LRP6ICD promotes Axin ubiquitination in Xenopus egg 
extract (Figure 3.3A). Furthermore, we show that inhibition of the proteasome with 
MG132 prevents Axin degradation, leading to accumulation of a more slowly migrating 
form of Axin (Figure 3.3B). Thus, our data indicate that, consistent with results from 
intact Xenopus oocytes (Kofron et al., 2007), Axin degradation is proteasome dependent 
in egg extract.  
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Figure 3.3:	  LRP6ICD mediates Axin degradation independently of GSK3 inhibition.  
(A)  LRP6ICD stimulates addition of GST-ubiquitin to radiolabeled, IVT Axin in egg 
extract.  GST-ubiquitin conjugates were pulled down with glutathione beads at indicated 
times and analyzed by SDS-PAGE and autoradiography.  Asterisk indicates full-length 
Axin. (B)  Addition of the proteasome inhibitor MG132 (1 mM) to egg extract inhibits 
LRP6ICD-mediated Axin degradation. (C)  Degradation of Axin mutants in egg extract 
in the presence of LRP6ICD.  RGS, RGS domain; GBS, GSK3 Binding Site; bBS, β-
catenin Binding Site; DIX, DIX domain.  The indicated LRP5/6 binding region on Axin 
is based on previous Axin-LRP5 and Axin-Arr yeast two-hybrid studies (Mao et al., 
2001b; Tolwinski et al., 2003); dotted lines represent large deletions of Axin that were 
not further mapped, and the borders of Axin-LRP5/6 interaction likely reside within the 
dotted lines.  (D) LRP6ICD promotes degradation of Axin and Axin375-869, whereas the 
GSK3 inhibitor BIO (50 mg/ml, Calbiochem) promotes degradation of Axin but not 
Axin375-869.  (E)  LRP6ICD promotes degradation of Axin and Axin375-869, whereas 
the GSK3 inhibitor LiCl (50 mM) promotes degradation of Axin but not Axin375-869.  
(F)  Inhibition of GSK3-mediated Axin phosphorylation (by LiCl (50 mM) or 
mutagenesis (AxinSA)), but not incubation with LRP6ICD, alters the trypsin proteolysis 
pattern of IVT Axin after incubation in egg extract for 30 min (note bands at level of 
asterisk).  All experiments used equal concentrations of IVT Axin.  An SDS-PAGE 
autoradiograph of IVT Axin and AxinSA prior to trypsin treatment is shown at right. 
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To uncover structural elements of Axin required for its LRP6-mediated 
degradation, we analyzed a panel of truncated Axin polypeptides. We identified a 
minimal Axin fragment (Axin375–809) that degrades in response to LRP6ICD (Figure  
3.3C, Figure 3.4).  This minimal fragment includes the GSK3, β-catenin, and PP2A 
binding sites on Axin (Fagotto et al., 1996). However, deletion of the GSK3 or β-catenin 
binding domain from full-length Axin does not prevent its LRP6ICD-mediated turnover 
(Figure 3.3C); thus, binding of Axin to GSK3 or β-catenin may not be required for 
LRP6-mediated degradation of Axin. Interestingly, amino acids 375–427 appear to be 
required in the large N-terminal truncation mutants (compare Axin375–809 and 
Axin427–809) but not in the internally truncated AxinΔGBS; we believe this may result 
from abnormal folding of certain truncation mutants, redundancy within Axin regarding 
sequences required for LRP6ICD-mediated Axin degradation, and/or dimerization of 
certain Axin mutants with endogenous Axin (Luo et al., 2005).  Notably, we find that the 
region of Axin identified as binding LRP5/6 by yeast two-hybrid assays (Mao et al., 
2001a; Tolwinski et al., 2003) also appears to be required for its LRP6-mediated 
degradation (Figure 3.3C). These data are consistent with a model in which LRP6/Axin 
binding is required for LRP6-mediated Axin degradation.  
Several models for Wnt pathway activation involve inhibition of GSK3, positing 
global inhibition of GSK3 within the cell or specific inhibition of GSK3 within the β-
catenin destruction complex. Either mechanism would allow β-catenin levels to rise 
because its phosphorylation, which is necessary for its degradation, is blocked. 
Experiments suggest an inherent feed-forward mechanism whereby GSK3 inhibition also 
stimulates Axin degradation by preventing phosphorylation of Axin, which is normally 
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required for its stability (Yamamoto et al., 1999). Thus, we tested whether LRP6ICD 
promotes Axin degradation by inhibiting GSK3-mediated phosphorylation of Axin.  
If LRP6ICD promotes turnover of Axin by inhibiting its GSK3-mediated 
phosphorylation, Axin mutants that degrade in response to LRP6ICD should also be able 
to degrade in response to GSK3 inhibition. Alternatively, if LRP6ICD-mediated Axin 
turnover does not occur via GSK3 inhibition, certain Axin mutants may degrade in 
response to LRP6ICD but not in response to GSK3 inhibition. We find evidence in 
support of the latter model. Both LRP6ICD and the GSK3 inhibitor BIO (Figure 3.3D) 
promote turnover of full-length Axin; in contrast, Axin375–869 degrades in response to 
LRP6ICD but not the GSK3 inhibitor BIO (Figure 3.3D). Another GSK3 inhibitor, 
lithium (50 mM), also promotes turnover of full-length Axin but not Axin375–869 (data 
not shown). Furthermore, Axin mutants lacking previously identified GSK3 
phosphorylation and binding sites as well as an Axin mutant (AxinSA) in which 
predicted GSK3 phosphorylated serines are mutated to alanines (Yamamoto et al., 1999) 
degrade in response to LRP6ICD (Figure 3.3C, Figure 3.4). Together, these data indicate 
that LRP6 is unlikely to promote Axin degradation via a mechanism that inhibits GSK3-
mediated stabilization of Axin.  
Distinct mechanisms underlying LRP6-mediated and GSK3 inhibition-mediated 
Axin degradation may induce different Axin conformations. Because changes in a 
protein's conformation may expose or conceal certain tryptic cleavage sites, a protein's 
tryptic proteolysis pattern is traditionally used to detect conformational changes (Liu et 
al., 2005; Moroney and McCarty, 1982; Stukenberg and Kirschner, 2001). Incubation of 
radiolabeled, IVT Axin in egg extract followed by partial trypsin proteolysis results in a  
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Figure 3.4:	   LRP6ICD stimulates degradation of Axin truncation mutants in egg 
extract.  (A)  IVT, radiolabeled Axin degradation assays in the presence or absence of 
LRP6ICD in Xenopus egg extract.   Samples were analyzed at either 0 hr and 3 hr (two 
lanes) or 0 hr, 1 hr, and 3 hr (three lanes).   In all experiments, wild-type Axin is used to 
confirm LRP6ICD activity (data not shown).   Amino acids corresponding to mAxin’s 
initiation methionine, RGS domain, GSK3 Binding Site, β-catenin Binding Site, and DIX 
domain are shown.   Axin with internal deletions of the GSK3 and β-catenin binding sites 
are AxinD298-437 and AxinD437-506, respectively.   Predicted GSK3 phosphorylation 
sites on Axin mutated in AxinSA are indicated with bold text.  (B)  To highlight effects 
of LRP6ICD on Axin stability, egg extracts with low basal Axin turnover were used for 
experiments in Figure  2.5A.   In other batches of egg extract, Axin truncation mutants 
lacking putative GSK3 phosphorylation sites shown to regulate Axin stability have 
increased rates of basal degradation compared to wild-type Axin.   In these extracts, 
LRP6ICD retains the ability to promote degradation of these Axin truncation mutants 
(data not shown). 
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characteristic Axin digestion pattern upon analysis by SDS/PAGE and autoradiography 
(Figure 3.3F). Trypsin digestion of Axin lacking GSK3 phosphorylation (either via 
mutation (AxinSA) or incubation with a GSK3 inhibitor (LiCl)) results in a proteolysis 
pattern distinct from that of wild-type Axin. Incubation of Axin with LRP6ICD, however, 
yields a digestion pattern that is indistinguishable from that of Axin alone. Because 
addition of LRP6ICD and inhibition of GSK3 phosphorylation have distinct effects on 
Axin conformation as assayed by trypsin digest, we propose that LRP6 signaling and 
GSK3 inhibition affect Axin through different mechanisms. These data are consistent 
with evidence in Drosophila embryos that Arrow, the Drosophila LRP5/6 ortholog, can 
promote Axin degradation in the absence of GSK3 activity (Tolwinski et al., 2003).  
  
LRP6ICD-mediated β-catenin stabilization does not require Axin degradation. 
Although we hypothesize that LRP6-mediated degradation of Axin, a required 
component of the β-catenin destruction complex, leads to β-catenin stabilization, we 
wanted to determine whether this is the only mechanism by which LRP6ICD stabilizes β-
catenin. To test this model, we assessed whether LRP6ICD can stabilize β-catenin in 
Xenopus egg extract in which endogenous Axin is replaced by a non-degradable Axin 
mutant, Axin1-713 (Figure 3.5D). Axin1-713, like full-length Axin, ventralizes Xenopus 
embryos (indicative of inhibition of Wnt/β-catenin signaling) (data not shown), 
stimulates β-catenin degradation and binds LRP6ICD in Xenopus egg extract (Figure 
3.5A,D). Thus, Axin1-713 retains all measurable activities of full-length Axin except that 
it is not degraded in response to LRP6ICD (Figure 3.3C). Consistent with the 
requirement of Axin for destruction complex formation, immunodepletion of endogenous  
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Figure 3.5:	   LRP6ICD promotes β-catenin stabilization in the absence of Axin 
degradation.  (A)  Axin and non-degradable Axin1-713, but not Axin1-427, bind 
LRP6ICD in egg extract.  Radiolabeled Axin, Axin1-713, and Axin1-427 were incubated 
with 6XHis-tagged LRP6ICD and pulled down with nickel beads.   Binding was 
performed in egg extract to increase the stringency of binding reaction conditions and 
because post-translational modification of LRP6 (e.g.  phosphorylation) is important for 
Axin/LRP6 binding.   The signal representing 10% of the total amount of IVT used in the 
binding experiments is indicated.   LRP6ICD increases the amount of Axin and Axin1-
713, but not Axin1-427, that is pulled down with nickel beads.   IVT Axin and Axin1-713 
pulled down with nickel beads in the presence of LRP6ICD also display a similar 
increase in mobility on SDS-PAGE.   These data suggest Axin and Axin1-713 bind LRP6 
in a similar manner.   Binding of nickel beads to 6XHis-tagged LRP6ICD occupies the 
Ni++ sites on the nickel resin, potentially blocking its nonspecific binding to IVT Axin.   
This likely explains why there is less IVT Axin background binding in the lane with 
LRP6ICD compared to IVT Axin alone.  (B)  Western blot confirms immunodepletion of 
Axin from Xenopus Egg Extract.  Axin immunoblot of mock (Protein A bead) and Axin-
depleted egg extract from Figures 2.7D.  Western blotting of tubulin is performed as 
loading control. (C)  Western blot confirms immunodepletion of Axin from Xenopus egg 
extract.  Axin immunoblot of mock (Protein A bead) and Axin-depleted egg extract from 
Figures 2.8D and 2.8E.  Western blotting of tubulin is performed as loading control.  (D)  
LRP6ICD inhibits β-catenin degradation in extract where endogenous Axin is replaced 
by non-degradable Axin1-713.  Addition of IVT Axin or Axin1-713 restores the ability of 
Axin-depleted extract to degrade radiolabeled β-catenin.  LRP6ICD inhibits both IVT 
Axin and Axin1-713-induced β-catenin-degradation.  
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Axin from extract (Figure 3.5B) prevented β-catenin degradation (Salic et al., 2000) 
(Figure 3.5D). Addition of IVT Axin1-713 to Axin-depleted extract restored β-catenin  
degradation to an extent similar to that of addition of full-length Axin. We then tested 
whether LRP6ICD inhibits β-catenin degradation in Axin1-713-rescued extract. As 
shown in Figure 3.5D, LRP6ICD inhibits β-catenin degradation in extract where 
endogenous Axin is replaced by either full-length Axin or non-degradable Axin1-713. 
Thus, LRP6ICD can inhibit β-catenin degradation independently of Axin degradation in 
Xenopus egg extract.  
  
LRP6ICD prevents GSK3-mediated phosphorylation of β-catenin. 
We next sought to identify the mechanism by which LRP6 stabilizes β-catenin 
independently of Axin degradation. It has been proposed that LRP6 might inhibit β-
catenin degradation by promoting dissociation of the β-catenin destruction complex 
(Nusse, 2005). To test this model, we immunoprecipitated Axin from Xenopus egg 
extract incubated in the presence or absence of LRP6ICD and immunoblotted for GSK3 
or β-catenin. As shown in Figure 3.6A and B, LRP6ICD (at a concentration that inhibits 
β-catenin degradation in Xenopus egg extract) does not affect Axin's ability to bind 
GSK3 or β-catenin. Thus, our data suggest that LRP6 does not sequester Axin from 
GSK3 or β-catenin.  
Alternatively, LRP6 could stabilize β-catenin by directly preventing its 
phosphorylation within the destruction complex. CK1α phosphorylates β-catenin at Ser-
45 (P45) to prime it for GSK3's phosphorylation at Ser-33/Ser-37/Thr-41 (P33/37/41),  
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Figure 3.6: LRP6ICD’s inhibition of GSK3-mediated β-catenin phosphorylation 
stabilizes β-catenin in the absence of Axin degradation.  (A)  LRP6ICD does not 
affect the ability of Axin to bind GSK3 or β-catenin in egg extract.  Endogenous Axin 
was immunoprecipitated from extract and immunoblotted for GSK3, β-catenin, and Axin.  
(B)  LRP6ICD Does Not Inhibit Myc-Tagged Axin Binding to GSK3 or β-catenin in Egg 
Extract.  IVT, Myc-Axin was incubated in egg extract in the presence or absence of 
LRP6ICD.   Myc-Axin was then immunoprecipitated with Myc-conjugated beads and 
immunoblotted for Myc, β-catenin, or GSK3.   IVT β-catenin was supplemented to 
extract to enhance its signal.  (C)  Incubation of LiCl (50 mM) or LRP6ICD (but not 
LRP6ICD(PPPAPX5)) in egg extract (30 min) inhibits phosphorylation of endogenous  
β-catenin at GSK3 target sites P33/37/41.  Immunoblot of LRP6ICD from the same gel 
reveals LRP6ICD, but not LRP6ICD(PPPAPX5), is phosphorylated at the PPPSP 
Ser1490.  All samples were blotted from a single gel.  (D)  Levels of endogenous β-
catenin in egg extract are not affected by Axin depletion.  Immunoblot for endogenous  
β-catenin demonstrates that manipulations shown in Figure 8E do not affect total β-
catenin levels.   This likely reflects the fact that the β-catenin involved in Wnt signal 
transduction represents only a small, cytoplasmic fraction of total β-catenin.   The vast 
majority of β-catenin in cells and egg extracts belongs to a stable, membrane-bound pool 
of β-catenin that is not normally regulated by the destruction complex or Wnt signaling 
(Heasman et al., 1994; Peifer et al., 1994).  (E)  LRP6ICD inhibits GSK3-mediated β-
catenin phosphorylation in extract in which endogenous Axin is replaced by non-
degradable Axin1-713.  Axin depletion did not affect total β-catenin levels as assayed by 
immunoblot.  Depletion of endogenous Axin prevents β-catenin P33/37/41 
phosphorylation.  Addition of IVT Axin1-713 restores β-catenin phosphorylation in 
Axin-depleted extract.  LRP6ICD inhibits IVT Axin1-713-induced β-catenin 
phosphorylation.  Extracts were analyzed after 2 hr incubation.  All samples were blotted 
from a single gel; intervening lanes were removed for clarity 
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which is required for β-catenin polyubiquitination and degradation (Liu et al., 2002). 
Previous studies showed that Wnt signaling inhibits GSK3-mediated β-catenin 
phosphorylation but does not inhibit CK1α-mediated β-catenin phosphorylation  (Liu et 
al., 2002). We therefore tested whether LRP6ICD inhibits the appearance of GSK3-
phosphorylated β-catenin in Xenopus egg extract. Significantly, LRP6ICD, like the 
GSK3 inhibitor lithium, inhibits GSK3-mediated phosphorylation of β-catenin (Figure 
3.6C). If LRP6 stabilizes β-catenin through inhibition of β-catenin phosphorylation, 
LRP6ICD's requirement for intact PPPSP motifs to stabilize β-catenin should extend to 
LRP6ICD's inhibition of β-catenin phosphorylation. Indeed, LRP6ICD(PPPAPX5), 
which does not inhibit degradation of β-catenin (Figure 3.1F), does not inhibit GSK3's 
phosphorylation of β-catenin (Figure 3.6C). Notably, we find that LRP6's PPPSP serine 
Ser-1490 is phosphorylated in extracts (Figure 3.6C). Thus, LRP6ICD inhibits 
phosphorylation of β−catenin, likely through a mechanism that requires serine 
phosphorylated PPPSP motifs.  
Phosphorylation of β-catenin by GSK3 requires its recruitment into the β-catenin 
destruction complex, which is mediated in part by Axin. Thus, it was possible that 
LRP6ICD-induced inhibition of GSK3's phosphorylation of β-catenin was a direct 
consequence of LRP6-mediated Axin degradation. To address this possibility, we tested 
whether LRP6ICD inhibits β-catenin P33/37/41 phosphorylation in Xenopus egg extract 
in which Axin is replaced by non-degradable Axin1-713 (Figure 3.6D,E) Axin depletion 
(Figure 3.5B) from extract inhibited GSK3's phosphorylation of β-catenin, consistent 
with Axin's role as a required scaffold for this phosphorylation event. Addition of non-
degradable IVT Axin1-713 to Axin-depleted extract restored β-catenin P33/37/41 
	   98 
phosphorylation. LRP6ICD blocked this Axin1-713-induced β-catenin phosphorylation 
(Figure 3.6D), demonstrating that LRP6ICD can inhibit phosphorylation of β-catenin by 
GSK3 independently of Axin degradation.  
LRP6ICD in Xenopus egg extract could specifically prevent β-catenin 
phosphorylation or act as a general GSK3 inhibitor (possibly by GSK3 sequestration) (Mi 
et al., 2006). If the former is correct, LRP6 should inhibit β-catenin phosphorylation 
without affecting phosphorylation of another GSK3 substrate (e.g., Tau) (Figure 3.7A). In 
Xenopus egg extract supplemented with exogenous GSK3, recombinant Tau is 
phosphorylated at its well characterized GSK3 target site Ser-396 (P396) (Hong et al., 
1997). In contrast to lithium, which robustly inhibits GSK3's phosphorylation of both β-
catenin and Tau, LRP6ICD inhibits phosphorylation of β-catenin but not of Tau. Thus, 
our data indicate that levels of LRP6ICD that stabilize β-catenin in egg extract inhibit 
GSK3-mediated β-catenin phosphorylation without affecting global GSK3 activity. Our 
finding that LRP6ICD does not act by inhibiting total GSK3 activity is also supported by 
our data demonstrating that LRP6ICD and lithium have distinct effects on Axin's trypsin 
proteolysis pattern and that LRP6 promotes Axin degradation independently of GSK3 
inhibition (Figure 3.3 C,D,E). Although previous experiments suggested that LRP6 
inhibits global GSK3 activity, the concentration of LRP6 intracellular domain in those 
experiments was not reported and may have been significantly greater than the 
concentration of LRP6ICD used in our experiments (Mi et al., 2006). Indeed, we detected 
inhibition of GSK3's phosphorylation of both β-catenin and Tau at higher concentrations 
of LRP6ICD than those required to inhibit β-catenin phosphorylation in our assays.  
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Figure 3.7 LRP6ICD directly and specifically inhibits GSK3’s phosphorylation of β-
catenin.  (A)  LiCl (50 mM) inhibits phosphorylation of β-catenin P33/37/41 and 
exogenous Tau P396 by GSK3, whereas LRP6ICD inhibits phosphorylation of β-catenin 
but not Tau by GSK3.  Extract was supplemented with GSK3 to enhance detection of 
phosphorylated Tau as previously described (Yost et al., 1998). β-catenin and Tau from 
the same reaction sample were immunoblotted from a single gel; intervening lanes were 
removed for clarity.  (B) and (D)  In an in vitro kinase assay containing purified, 
recombinant Axin (0.1 µM), GSK3 (0.79 µM), CK1 (1.37 µM), Tau (0.34 µM) and β-
catenin (0.22 µM), LRP6ICD (4.1 µM) inhibits phosphorylation of β-catenin P33/37/41 
by GSK3 without inhibiting the phosphorylation of Tau P396 by GSK3.  (C)  LRP6ICD 
does not inhibit CK1 phosphorylation of β-catenin in vitro.  In an in vitro kinase assay 
with recombinant, purified proteins, LRP6ICD does not inhibit phosphorylation of β-
catenin P45 by CK1.   For this figure, nitrocellulose membrane from Figure 2.9B was 
stripped and re-blotted with antibody to β-catenin P45.  (E)  In a kinase reaction in which 
recombinant Axin is absent, phosphorylation of β-catenin by GSK3 is inhibited by 
LRP6ICD but not by LRP6ICD(PPPAPX5).  For (B), (C), (D), and (E), β-catenin and 
Tau were incubated in the same reaction and immunoblotted from a single gel. 
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LRP6ICD directly inhibits GSK3-mediated β-catenin phosphorylation. 
The simplest model for LRP6 signaling is that it directly inhibits β-catenin 
phosphorylation by GSK3. Alternatively, LRP6-mediated inhibition of β-catenin 
phosphorylation may require additional components. To determine whether LRP6ICD is 
sufficient to inhibit GSK3-mediated β-catenin phosphorylation, we tested whether we 
could reconstitute LRP6 signaling with purified components.  
In a kinase assay with purified, recombinant proteins, LRP6ICD inhibits GSK3-
mediated phosphorylation of β-catenin at P33/37/41 without inhibiting CK1's 
phosphorylation of β-catenin at P45 (Figure 3.7 B,C,D).  Importantly, the concentration 
of LRP6ICD tested does not inhibit GSK3's phosphorylation of Tau in the same reaction, 
demonstrating that inhibition of β-catenin phosphorylation by LRP6ICD is not a result of 
general inhibition of GSK3 activity (Figure 3.7 B,C). Thus, LRP6ICD preferentially 
inhibits GSK3's phosphorylation of β-catenin in a kinase assay with purified components.  
The ability of GSK3 to phosphorylate β-catenin independently of Axin (albeit 
inefficiently) in our purified system allowed us to test whether LRP6ICD inhibits GSK3's 
phosphorylation of β-catenin directly or indirectly (via a conformational change of Axin 
upon its binding to LRP6ICD). Significantly, we find that Axin is not required for 
LRP6ICD's inhibition of β-catenin P33/37/41 phosphorylation (Figure 3.7B). In addition, 
CK1γ's phosphorylation plays a role in LRP6 signaling in vivo (Davidson et al., 2005), 
but CK1 is not required for LRP6ICD activity in our kinase assay (Figure 3.7B,D). These 
results demonstrate that LRP6ICD can directly inhibit GSK3-mediated phosphorylation 
of β-catenin and that this inhibition does not require other components.  
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Next, we tested whether LRP6 requires intact PPPSP motifs to inhibit GSK3's 
phosphorylation of β-catenin in our purified system. Unlike LRP6ICD, 
LRP6ICD(PPPAPX5) does not inhibit GSK3's phosphorylation of β-catenin (Figure 
3.7E), demonstrating that LRP6's PPPSP motifs are required for LRP6 to inhibit β-
catenin phosphorylation in vitro. In a kinase assay with recombinant proteins, GSK3 
phosphorylates LRP6 in a manner that requires intact PPPSP motifs (data not shown) (Mi 
and Johnson, 2005). Thus, we infer that phosphorylation of PPPSP serines by GSK3 is 
required for LRP6's ability to inhibit β-catenin phosphorylation in our purified, 
reconstituted system. Our purified system exhibits specific properties that are consistent 
with in vivo and egg extract data: (i) requirement for PPPSP serines (Tamai et al., 2004) 
(Zeng et al., 2005), (ii) specificity for inhibition of β-catenin and not Tau phosphorylation 
(Figure 3.11A), and (iii) inhibition of β-catenin phosphorylation by GSK3 but not CK1 
(Liu et al., 2002). Thus, we believe these studies recapitulate distinct properties of LRP6 
signaling in vivo.  
 
LRP6ICD associates with β-catenin in vivo 
Given that LRP6ICD is sufficient to inhibit GSK3-mediated β-catenin 
phosphorylation in a kinase assay with purified proteins, we hypothesized that LRP6ICD 
may directly interact with β-catenin to prevent its GSK3-mediated phosphorylation. To 
determine whether β-catenin and LRP6ICD can interact in cultured mammalian cells, we 
performed bimolecular fluorescence complementation (BiFC) between β-catenin and 
LRP6ICD (Hu et al., 2002). In this assay, interacting proteins that are fused to N- and C-
terminal halves, respectively, of YFP bring the two halves of YFP in close enough 
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association to produce a functional, fluorescent YFP molecule. BiFC-mediated 
fluorescence requires a relatively stable protein–protein interaction in the range of several 
seconds and detects direct or very close interactions within protein complexes (Hu et al., 
2002). Similar to fluorescence energy transfer (FRET), BiFC indicates a potential for 
physical interaction in a cell. As a positive control, cells transfected with N- and C-
terminal halves of YFP fused to separate glutathione S-transferase (GST) proteins (which 
have been shown to oligomerize) produce cytoplasmic YFP fluorescence in ≈50% of 
cells (Figure 3.8). In contrast, none of the cells transfected with N-and C-terminal halves 
of YFP fused to LRP6ICD and GST, respectively, or fused to GST and β-catenin, 
respectively, produce any detectable fluorescent signal (Figure 3.13). In addition, the 
individual fusion proteins, when expressed in cells alone, do not produce fluorescence 
(data not shown). Importantly, cells transfected with N- and C-terminal halves of YFP 
fused to LRP6ICD and β-catenin, respectively, produce functional, fluorescent YFP in 
≈15% of cells (Figure 3.8). These results indicate that LRP6ICD and β-catenin form a 
stable interaction in vivo (likely within the Axin complex).  
  
Discussion 
We provide evidence that LRP6 can promote β-catenin stabilization 
independently of Axin degradation by inhibiting GSK3's phosphorylation of β-catenin. 
This mechanism is consistent with cultured cell experiments demonstrating Wnt-
mediated stabilization of β-catenin in the absence of Axin degradation (Liu et al., 2005). 
Intriguingly, we find that LRP6 directly and specifically inhibits GSK3's phosphorylation  
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Figure 3.8 BiFC analysis of LRP6ICD and β-catenin interaction in vivo.  
Fluorescence is detected in HEK293 cells transfected with plasmids encoding LRP6ICD-
YN plus β-catenin-YC and GST-YN plus GST-YC (positive control).   No fluorescence 
is detected in cells transfected with plasmids encoding LRP6ICD-YN plus GST-YC, β-
catenin-YC plus GST-YN, or any of the individual fusion constructs.  YN and YC 
represent the N-terminal (1-154) and C-terminal (155-238) halves of YFP, respectively.  
DAPI staining (blue) is used to visualize cell nuclei.  
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of β-catenin in vitro, independently of Axin. It has been previously shown that addition 
of Wnt ligand to cultured mammalian cells rapidly induces recruitment of Axin to 
LRP5/6 (Mao et al., 2001b). We propose that this interaction between LRP5/6 and Axin 
serves to bring LRP5/6 in close proximity to β-catenin and GSK3, allowing for inhibition 
of β-catenin phosphorylation. Consistent with this hypothesis, we find that LRP6ICD and 
β-catenin can interact in cultured cells. We also find that LRP6 requires intact PPPSP 
motifs to directly inhibit GSK3's phosphorylation of β-catenin. Thus, we propose the 
following working model. A Wnt signal induces GSK3's and CK1γ's phosphorylation of 
LRP5/6, which promotes the binding of Axin to LRP5/6 (Davidson et al., 2005; Zeng et 
al., 2005).  Axin thereby brings β-catenin and GSK3 in close proximity to LRP5/6 where 
its phosphorylated PPPSP motifs are involved in mediating inhibition of GSK3's 
phosphorylation of β-catenin. Analysis of the molecular details of this interaction may 
help elucidate the mechanism by which LRP6 prevents β-catenin phosphorylation.  
Because Axin is the limiting factor in β-catenin destruction complex formation, 
we predict that Axin degradation (although not required for all aspects of β-catenin 
stabilization) plays an important role in LRP5/6-mediated Wnt signal transduction (Lee et 
al., 2003).  Thus, we suggest that both LRP5/6-mediated inhibition of β-catenin 
phosphorylation and stimulation of Axin degradation contribute significantly to Wnt/β-
catenin signaling. The existence of two mechanisms by which LRP5/6 mediates β-catenin 
stabilization may allow for more robust transduction of a Wnt signal. Furthermore, these 
two mechanisms are fundamentally different and could lead to distinct downstream 
responses. Regulation of the relative contributions of both mechanisms for stabilizing β-
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catenin would allow an organism to fine-tune sensitivity to Wnt signals for precise 
temporal and spatial control of tissue patterning. Moreover, it is likely that additional 
mechanisms not described here further contribute to the robustness and regulation of 
Wnt-mediated β-catenin stabilization (Liu et al., 2005). 
  
Future Directions 
 
Mechanism for direct inhibition of GSK3 by LRP6 
 We have shown that LRP6ICD can inhibit GSK3 kinase activity towards β-
catenin in vitro.  A recent study has found that activation of the Wnt pathway results in 
recruitment of dephosphorylated β-catenin to the membrane (Hendriksen et al., 2008). 
We also know that Axin is recruited to LRP6 at the membrane in response to Wnt 
signaling (Mao et al., 2001b), and that LRP6 PPPSP domains are required for Axin 
binding (Tamai et al., 2004).  We have found that LRP6 PPPSP are also required for 
inhibition of GSK3 kinase activity towards β-catenin.  This has led us to propose that 
interaction between LRP6 and Axin brings LRP6 in close proximity to β-catenin and 
GSK3 allowing for inhibition of β-catenin phosphorylation.  However, evidence suggests 
that the PPPSP motifs on LRP6 are phosphorylated by GSK3 indicating that the substrate 
(LRP6) of the kinase (GSK3) once phosphorylated inhibits the kinase.  This suggests that 
significant structural changes take place after LRP6 is phosphorylated that results in its 
capability to inhibit GSK3 activity.  Additionally, Axin may be important for the 
mechanism of LRP6 inhibition of GSK3.  Structural analysis of the phosphorylated 
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LRP6-GSK3 complex (with Axin and/or β-catenin) will provide significant insight into 
the mechanism of LRP6 inhibition of GSK3 activity. 
  
Mechanism for Axin degradation 
 Consistent with previously proposed models for LRP6 signaling, we demonstrate 
that LRP6ICD stimulates ubiquitin-mediated degradation of IVT Axin and Axin2 (Mao 
et al., 2001b; Tolwinski et al., 2003). We also found that LRP6ICD induces 
phosphorylation of Axin and that λ-phosphatase reverses the LRP6ICD-mediated 
phosphorylation. Total Axin signal is decreased after treatment with LRP6ICD even after 
λ-phosphatase treatment, consistent with LRP6ICD mediating Axin degradation.  Since 
evidence suggests that Axin is a limiting component of the destruction complex (Lee et 
al., 2003), modulation of Axin levels can have a strong effect on pathway activity.  
However, the mammalian tissue culture experiments, Axin degradation lags behind β-
catenin stabilization indicating that regulation of Axin stability is not a primary means of 
stabilizing β-catenin (Liu et al., 2005; Willert et al., 1999; Yamamoto et al., 1999).    Due 
to Axin’s role as a tumor suppressor, targeting Axin protein stability could be 
advantageous in treating colon cancer.  Identification of Axin’s E3-ubiquitin ligase would 
provide insight into the mechanism of Axin degradation.   Additionally, it would 
beneficial to conduct a mutagenesis analysis of the candidate lysines in Axin that are 
ubiquitinated in response to LRP6 activation. 
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LRP6ICD as a tool to identify small molecule inhibitors of Wnt/β-catenin signaling. 
Since LRPICD can stabilize β-catenin and induce Axin degradation in Xenopus 
egg extracts, a high throughput screen was designed to indentify small compounds that 
could reverse the effects of LRP6ICD on the both the stability of Axin and β-catenin 
(Cselenyi et al., 2008).  This is in effort to identify novel compounds for therapeutic 
treatment of conditions resulting from over-activation of Wnt/β-catenin signaling.  To 
monitor Axin and β-catenin protein stability at the same time Axin was tagged with 
Renilla luciferase and β-catenin was tagged with firefly luciferase. The reciprocal 
stability of β-catenin (increased) and Axin (decreased) in response to LRP6-mediated 
signaling provides a simple strategy for identified false positive small molecules such that 
compounds that interfere with energy metabolism would reduce both firefly and Renilla 
luminescent signals. Conversely, general inhibitors of protein degradation (e.g. 
proteasome inhibitors) would block both β-catenin and Axin degradation, leading to 
coincident enhancement of both firefly and Renilla luciferase signals.  Using an FDA 
approved drug library from the National Institute of Neurological Disorders at the 
Harvard Medical School Institute for Chemistry and Cell Biology (ICCB) about 38 
chemical inhibitors and activators were identified (Curtis Thorne (CT), unpublished 
results).  One of these chemical inhibitors identified, WS-30, potentially inhibits Wnt/β-
catenin signaling in Xenopus egg extract, mammalian culture cells, Xenopus embryos, 
Drosophila embryos, and in C. elegans (CT, unpublished results).  In mammalian culture 
cells, WS-30 inhibits Wnt3a-mediated luciferase activity in a dose-dependent manner 
with an EC50 of ~10 nM. This small molecule can inhibit β-catenin degradation, 
stimulate Axin degradation, as well as stimulate Pygopus (a nuclear factor required for β-
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catenin-mediated transcription) degradation indicating that either WS-30 targets each of 
these proteins individually, or it targets a protein that affects each of the proteins’ 
stability.  The latter option was found to be the case in that WS-30 binds to and stimulates 
casein kinase 1 alpha (CK1α) kinase activity, resulting in Axin degradation, β-catenin 
stabilization, and Pygopus degradation (CT, unpublished results). Additional studies for 
this small molecule as a potential therapeutic agent are ongoing. 
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